RRI-Final-hi-res-rgb

**Pravin U. Dugel, MD**

**Curriculum Vitae**

**Retinal Consultants of Arizona, LTD**

15401 North 29th Avenue.

Phoenix, AZ 85053

602-222-2221

[**pdugel@gmail.com**](mailto:pdugel@gmail.com)

**Retinal Research Institute, LLC**

15401 N. 29th Avenue              1101 E. Missouri Avenue                     1712 E. Boston Street

Phoenix, AZ  85053                    Phoenix, AZ  85014                              Gilbert, AZ  85296

Pravin U. Dugel, MD graduated Summa Cum Laude from Columbia University in the City of New York and also was a four-year starter and the captain of the Squash team. He then attended UCLA School of Medicine. He completed his residency in ophthalmology at the USC Eye Institute, Keck School of Medicine. Thereafter, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and his surgical retina fellowship at the USC Eye Institute, where he was elected to serve on the faculty as the Resident Director.

Dr. Dugel joined Retinal Consultants of Arizona in July 1994 and is currently Managing Partner, Retinal Consultants of Arizona; Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; Founding Member, Spectra Eye Institute, Sun City; Physician Executive Director, Banner Eye Institute, Banner University Medical Center, University of Arizona.

Dr. Dugel has authored more than 200 papers, 35 book chapters and has been invited to lecture at prestigious meetings, Visiting Professorships and Universities worldwide, including Japan, India, China, Malaysia, Egypt, United Kingdom, France, Germany, Austria, Italy, Poland, Denmark, Norway, Czechoslovakia, Canada and Australia. He is on the Editorial Board of several major-medical journals. Dr. Dugel is internationally recognized as a major clinical researcher and has been a primary investigator in over 100 multicenter clinical trials. His research and educational contributions earned him the prestigious Senior Honor Award from the American Academy of Ophthalmology (AAO). He has been elected Subspecialty Day Board Chairman for the American Academy of Ophthalmology, to the Board of Directors of the largest retina society in the USA, American Society of Retina Specialists (ASRS), and to the largest retina society in Europe, EuRetina. He serves on the Scientific Advisory Board of numerous companies, including Aerpio, Alcon, Digisight, Genentech, Novartis, Ophthotech, Opthea, Roche, Allegro Ophthalmics and TrueVision.

In Arizona, he has served as President of the Phoenix Ophthalmology Society and is on the Board of Directors of the Arizona Ophthalmology Society. Since 1994, Dr. Dugel has been a member of the U.S. Department of Health and Human Services agency, providing eye care services to Native Americans. He has co-founded a scholarship and mentorship program - Project SENA - with his two daughters, creating educational opportunities for Native American youth and adults.

Dr. Dugel is a member of the Board of Directors and current Chair of Orbis International’s Medical Advisory Board/Medical Strategic Committee. With Orbis, he travels to developing countries to teach surgical techniques to local ophthalmologists and provide free surgery for those suffering from preventable blindness.

Dr. Dugel has received numerous awards and honors including amongst others, the Heed Foundation Fellowship Award, The Ronald G. Michels Surgical Fellowship Award, AAO Senior Honor Award, AAO Honor Award, the AAO Secretariat Award, the Sally Letson Award, and USC Alumnus of the Year Award. Dr. Dugel was honored to deliver the Alex E. Krill MD, Gabriel Cosas MD and Paul K. Nase MD Memorial Lectures and has been named "one of the best 35 ophthalmologists in the USA" by the Becker Institute. In 2017, Dr. Dugel was inducted into the “Retina Hall of Fame,” which honors ophthalmologists for their exceptional lifetime achievements and contributions to the field of retina.

**Index**

[Education](#Education)

[Postgraduate and Fellowship Training](#PostgraduateandFellowshipTraining)

[Work Experience](#WorkExperience)

[Academic Appointment](#AcademicAppointment)

[Clinical Faculty](#ClinicalFaculty)

[Specialty Certification](#SpecialtyCertification)

[Licensure](#Licensure)

[Awards, Honors, and Membership - Honorary Societies](#AwardsHonorsMemberships)

[Academic and Administrative Appointments](#AcademicandAdministrativeAppointments)

[Scientific and Investigative Positions](#ScientificInvestigativePositions)

[Patents](#Patents)

[Peer Reviewed Journals](#PeerReviewedJournals)

[Non- Peer Reviewed Journals](#NonPeerReviewedJournals)

[Book Chapters](#BookChapters)

[Book Review](#BookReview)

[Correspondence](#Correspondence)

[Invited Presentations](#InvitedPresentations)

[Journal Scientific Review Committee](#JournalScientificReviewCommittee)

[Scientific Advisory Board](#ScientficAdvisoryBoard)

[Consultant](#Consultant)

**Education**

**1976 – 78**

Harrow-On-The-Hill

London, England

**1978 – 80**

United Nations International School

New York, New York

**1980 – 84**

Bachelor of Arts (BA)

Comparative Literature & Molecular Biology

Columbia University

New York, New York

**1984 – 88**

Doctor of Medicine (MD)

University of California, Los Angeles

David Geffen School of Medicine

Los Angeles, California

**Postgraduate and Fellowship Training**

**1988 – 89**

Internship

Los Angeles County / USC Keck School of Medicine

Los Angeles, California

**1989 – 92**

Residency

Roski Eye Institute

Keck School of Medicine

University of Southern California

Los Angeles, California

**1992**

Fellowship, Vitreoretinal Surgery (Surgical Retina)

Roski Eye Institute,

USC Keck School of Medicine

University of Southern California

Los Angeles, California

**1993**

Fellowship, Vitreoretinal Diseases (Medical Retina)

Bascom Palmer Eye Institute

University of Miami School of Medicine Miami, Florida

**1993 – 94**

Resident Supervisor

Roski Eye Institute

University of Southern California

USC Keck School of Medicine

Los Angeles, California

**1993 – 94**

Chief, Vitreoretinal Diseases and Surgery

Los Angeles County/USC Keck School of Medicine

Los Angeles, California

******Work Experience**

**1994 – Present**

**Managing Partner**

Retinal Consultants of Arizona

Retinal Research Institute

RRI-Final-hi-res-rgb

**2015-Present**

**Physician Executive Director**

Banner University Medical Center

Banner Eye Institute

**Academic Appointment**



Clinical Professor – Department of Ophthalmology

Roski Eye Institute

USC Keck School of Medicine

University of Southern California

Los Angeles, California



**Clinical Faculty**

Department of Ophthalmology

University of Arizona School of Medicine Tucson, Arizona

**Specialty Certification**

American Board of Ophthalmology

**Licensure**

Arizona & California

**Awards, Honors, and Membership in Honorary Societies**

**2016**

University of Southern California Alumnus Award

**2015**

Chair the 2015 American Academy of Ophthalmology Retina Subspecialty Day

**2014**

Sally Letson Award, Canadian Ophthalmology Society

**2010**

Secretariat Award, American Academy of Ophthalmology

Senior Achievement Award, American Academy of Ophthalmology

Named one of the 34 best ophthalmologists in the country by Becker’s ASC Review

**2009**

American Society of Retina Specialists Honor Award

**1996**

American Academy of Ophthalmology Honor Award

**1992 – 93**

Heed Ophthalmic – Doheny Eye Institute Fellowship Award

Ronald G. Michels Vitreoretinal Surgery Fellowship Award – Doheny Eye Institute

**1992**

Pacific Coast Ophthalmology Research Award – Doheny Eye Institute

**1984**

Columbia Squash – Columbia University Alumni Cup

**1982 – 84**

Captain – Columbia University Squash Team

**1980 – 84**

Deans Honor Society – Columbia University

**1980**

Summa Cum Laude – Columbia University

**1979**

Phi Beta Kappa – Columbia University, Honors Student Society

**1976**

Best Study – Harrow-On-The-Hill, Scholarship

**Academic and Administrative Appointments**

**2017 – Present**

Member, Board of Directors

Orbis International

**2016 – Present**

Clinical Faculty, Department of Ophthalmology

University of Arizona School of Medicine

Tucson, Arizona

**2015 – Present**

Physician Executive Director

Banner Eye Institute

Banner University Medical Center

**2015 – Present**

Clinical Professor – Department of Ophthalmology

Roski Eye Institute, USC Keck School of Medicine

**2015 – Present**

Board of Directors, European Retina Society

**2014 – Present**

Member, Ophthalmology Advisory Board, Annidis

**2014 – Present**

Chairman, Medical Advisory Committee

Orbis International

**2011 –2015**

Chairman, Therapeutics Surveillance Committee, American Society of Retina Specialists (ASRS)

**2010 – Present**

Member, European Vitreo Retinal Society

**2010-Present**

Treasurer, Outpatient Ophthalmic Surgery Society (OOSS)

**2009 – Present**

ASRS Liaison, AAO Health Policy Committee

**2009 – Present**

Editorial Board, Retina Today

**2009 – Present**

Editorial Board, Retina Times

**2009 – Present**

Editorial Board, Retinal Physician

**2009 – Present**

Committee Representative, RUC, American Society of Retina Specialists (ASRS)

**2009 – Present**

Committee Liaison, RUC, American Society of Retina Specialists (ASRS)

**2009 – Present**

Communications Advisory Board, American Academy of Ophthalmology

**2009 – Present**

Chairman, American Academy of Ophthalmology (AAO) Media Relations Committee

**2008 – Present**

Elected Member, The Retina Society

**2008 – Present**

Elected Member, Macula Society

**2008 – Present**

Board of Directors, American Society of Retina Specialists (ASRS)

**2008 – Present**

Chairman, Research and Therapeutics Committee, American Society of Retina Specialists (ASRS)

**2007 – Present**

Avastin Access Committee, American Society of Retina Specialists (ASRS)

**2007 – Present**

Associate Editor in Chief, Current Concepts in Retina

**2007 – Present**

Board of Directors, Outpatient Ophthalmology Surgery Society (OOSS)

**2007 - 2010**

Board of Directors, Outpatient Ophthalmic Surgery Society (OOSS)

**2000 – Present**

Board of Directors, University of Arizona, Department of Ophthalmology

**1999 – Present**

Executive Committee, Arizona Ophthalmology Society

**1998 – Present**

Chairman, Annual Meeting, Arizona Ophthalmology Society

**1998 – 99**

President, Phoenix Ophthalmology Society

**1996 – Present**

Executive Committee, Phoenix Ophthalmology Society

**1995 – Present**

Elected Member, American Society of Retina Specialists (ASRS)

**1995 – Present**

Member, Arizona Ophthalmology Society

**1994 – Present**

Member, The Western Retina Study Club

**1994 – 99**

Ophthalmology Committee, Board of Directors, St. Luke’s Hospital

**1993 – Present**

Member, The American Society of Retina Surgeons (ASRS)

Member, The Ronald G. Michels Fellowship Award Foundation

Member, The Heed Fellowship Foundation

**1992 – 96**

Member, Recertification Committee, American Academy of Ophthalmology (AAO)

**1990 – 94**

Member, American Uveitis Society

**1989 – Present**

Member, American Academy of Ophthalmology (AAO)

**1989 – Present**

Member, Association for Research in Vision and Ophthalmology

**1989 – 95**

Board of Directors, California Association of Ophthalmology

**1989 – 94**

Member, Los Angeles Society of Ophthalmology

**1984 – Present**

Member, American Medical Association

**1984 – 94**

Member, Los Angeles Medical Association

**Scientific and Investigative Positions**

**2018**

Principal Investigator, A Phase I Open Label, Multi-center Study to Investigate Ocular and Systemic Safety, Tolerability, and Pharmacokinetics following a Single Intravitreal. Administration of KSI-301 in Subjects with Center Involved Diabetic Macular Edema (DME). Sponsor: Kodiak

Principal Investigator, A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration – 22-month study. Sponsor: Chengdu Kanghong Biotechnology

Principal Investigator, A Prospective Single-Center Study to Evaluate the Safety, Performance and Efficacy of the BeyeOnics Ophthalmic Augmented Reality Video Microscope (ARVM) for Assisting in Ophthalmic Surgery Procedures. Sponsor: BeyeOnics

Principle Investigator, A Phase 1, open-label, multicenter, dose escalation study to evaluate the safety of a single intravitreal injection of THR-149 for the treatment of diabetic macular edema (DME) 3-4-month study. Sponsor: Thrombogenics

Principal Investigator, Phase 1B/2A Study of OPT302 in Combination with Aflibercept for Persistent Central-Involved Diabetic Macular Edema. Sponsor: Opthea

Principal Investigator, The Correlation of Paxos Checkup Mobile App to Standard in Office Visual Assessment (Clear). Sponsor – DigiSight Technologies, Inc. Prospective, Multicenter, Single-arm Study, Two Phases (pilot and Pivotal) Open Label for patients with AMD, DR/DME or Normal Vision. Sponsor: Digisight

Investigator, Phase 2A Open Label Trial to Assess the Safety of Zimura Administered in Combination with Lucentis in Subjects with Treatment Naïve Neovascular Age Related Macular Degeneration. Sponsor: Ophthotech

Investigator, Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15 MG Once Daily or 15 MG Twice Daily for 12 Months in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathy. Sponsor: Aerpio

Investigator, A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. Sponsor: Ophthotech

Investigator, A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease. Sponsor: Ophthotech

Investigator, Phase II Randomized, Controlled, Double-Masked, Crossover Clinical Trial designed to Evaluate the Safety and Exploratory Efficacy of 1.0 mg Luminate (ALG-1001) as a Treatment for Non-Exudative Macular Degeneration – 8-month. Sponsor: Allegro

Investigator, A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in combination with an intravitreal anti-VEGF agent in subjects with retinal vein occlusion – 12-month study. Sponsor: Clearside

**2017**  
Principal Investigator, A Dose Ranging Study of Intravitreal OPT-302 in Combination with Ranibizumab, Compared to Ranibizumab Alone, in Participants with Neovascular Age-Related Macular Degeneration. Sponsor: Opthea OPT302­

Principal Investigator, Phase I/IIA Safety Study of Subretinal Implantation of CPCB-RPE1 (Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial (RPE) Cells Seeded on a Polymeric Substrate) in Subjects with Advanced, Dry Age-Related Macular Degeneration (AMD) (5-year study). Sponsor: USC RPT

Principal Investigator, A Phase 3 Randomized, Double-Masked, Vehicle-Controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Topical Ocular Formulation in Subjects with Non-Infectious Anterior Uveitis). Sponsor: Aldeyra

Principal Investigator, A Multicenter, Randomized, Active Comparator Controlled Phase II Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered at 12 and 16 Week Intervals in Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Sponsor: Roche “Stairway”

Principal Investigator, The Correlation of Paxos Checkup Mobile App to Standard in Office Visual Assessment (Clear). Sponsor – DigiSight Technologies, Inc. Prospective, Multicenter, Single-arm Study, Two Phases (pilot and Pivotal) Open Label for patients with AMD, DR/DME or Normal Vision. Sponsor: DigiSight

Principal Investigator, A Multi center, Multiple Dose, randomized active comparator controlled, double-masked, parallel group, 24-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in *NAÏVE* patients with Diabetic Macular Edema. Sponsor: Boulevard

Principal Investigator, A Phase 2 Multicenter, Randomized, Double‐Masked, Placebo‐Controlled, Pilot Study to Evaluate Effects of Emixustat Hydrochloride on Aqueous Humor Biomarkers Associated with Proliferative Diabetic Retinopathy. Sponsor: Acucela

Principal Investigator, A Prospective, Multicenter Clinical Trial of the Implantable Miniature Telescope in Pseudophakic Eyes with Central Vision Impairment associated with End-Stage Macular Degeneration. Sponsor: IMT-TES

Investigator, Phase 2A Open Label Trial to Assess the Safety of Zimura Administered in Combination with Lucentis in Subjects with Treatment Naïve Neovascular Age Related Macular Degeneration. Sponsor: Ophthotech OPH2007

Investigator, Randomized, Controlled, Double-Masked, Crossover Clinical Trial designed to Evaluate the Safety and Exploratory Efficacy of 1.0 mg Luminate (ALG-1001) as a Treatment for Non-Exudative Macular Degeneration. Sponsor: Allegro Dry AMD

Investigator, Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15 MG Once Daily or 15 MG Twice Daily for 12 Months in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathy. Sponsor: Aerpio

Investigator, Phase I/II Multicenter Study Evaluating the Safety, Tolerability and Efficacy of an Intravitreal Depot Formulation of GB-102 in Subjects with Neovascular Age-related Macular Degeneration. Sponsor: Greybug Vision “Adiago”

Investigator, Phase III, multi-Center, Randomized, Masked, Controlled, Parallel Arm Clinical Trial to Study the Safety and Efficacy of a proprietary Formulation of the study drug in conjunction with an Anti-VEGF agent in CRVO and BRVO patients. Sponsor: Allergan

Investigator, A Phase IIa trial of an intravitreal liposomal form of steroid in patients with Macular Edema due to Central Retinal Vein Occlusion: A double-masked, randomized trial to evaluate efficacy and tolerability Treatment Groups: 3 different dose strengths of an intravitreal liposomal form of steroid will be evaluated. Single intravitreal injection to the study eye administered by investigators on Day 1. Sponsor: Taiwan Liposome Company, LTD

Investigator, External Natural History Controlled, open-Label Intervention Study to assess the Efficacy and Safety of Long-Term Treatment with Raxone in Leber’s Hereditary Optic Neuropathy.Sponsor: Santhera

Investigator, Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration. Sponsor: Allergan Sequoia

Investigator, Phase III Study of the Safety and Efficacy of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Sponsor: OHR

Investigator, Randomized, Double Masked, Controlled Study Comparing the Safety and Efficacy of Suprachoroidal CLS-TA with Intravitreal Aflibercept versus Aflibercept Alone in Subjects with Diabetic Macular Edema (24 week study). Sponsor: Clearside Tybee

Investigator, Multi-Center, Non-Interventional Extension Study of the Safety and Efficacy of CLS-TA for the Treatment of Macular Edema associated with Non-Infectious Uveitis. Sponsor: Clearside Magnolia

Investigator, Phase 3 trial to study the safety and efficacy of Triamcinolone Acetonide Suspension (CLS-TA) for the treatment of macular edema secondary to non-infectious uveitis. Sponsor: Clearside Peachtree

Investigator, Phase III, multi-Center, Randomized, Masked, Controlled, Parallel Arm Clinical Trial to Study the Safety and Efficacy of a proprietary Formulation of the study drug in conjunction with an Anti-VEGF agent in CRVO and BRVO patients. Sponsor: Clearside Sapphire

Investigator, Internal OCTA Study in conjunction with USC of Patients with Diabetes and VA 20/20-20/400 having Zeiss 7 Standard Field Fundus Photos and Zeiss OCT Angiography. Internal

Investigator, A Multi-Center, Prospective, Randomized Non-Inferiority Trial of Eyes with macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab every 4 weeks with Intravitreal Aflibercept every 4 weeks. Sponsor: Score 2

Investigator, A Phase IIa trial of an intravitreal liposomal form of steroid in patients with Macular Edema due to Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion: A double-masked, randomized trial to evaluate efficacy and tolerability. Treatment Groups: 3 different dose strengths of an intravitreal liposomal form of steroid will be evaluated. Single intravitreal injection to the study eye administered by investigators on Day 1. Sponsor: ORA Wood

Investigator, Open Label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectible Suspension in Patients with Non-Infectious Uveitis. Sponsor: Clearside Azalea

**2016**

Principal Investigator, Subjects with Neovascular age-related macular degeneration. Evaluate the safety and tolerability of singly ascending intravitreal LMG324 doses to determine the maximum tolerated dose (MTD) in treatment naïve Neovascular age related macular degeneration (nv AMD) SUBJECTS.  To be administered every 4 weeks with respect to change from baseline in best-corrected visual acuity after 12 weeks. Sponsor: Alcon

Principal Investigator, A Multi-Center Multiple Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmakinetics, amd Efficacy of RO6867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Sponsor: Roche Avenue

Principal Investigator, Phase 1 Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 (anti-VEGF-C and -D) in combination with Ranibizumab in subjects with wet AMD Design: Two-part study: Part 1 consists of 3 sequential, escalating cohort dose levels of OPT-302 each used in combination with Ranibizumab; and one additional monotherapy cohort dose level of OPT-302. This is followed by Part 2, a 2-arm study (1:1) evaluating OPT-302 at the MTD in combination with Ranibizumab q4 weeks versus OPT-302 monotherapy q4 weeks. Sponsor: Opthea

Principal Investigator, Phase 1 dose escalation and expansion study of DS7080a in subjects with neovascular age-related macular degeneration. Sponsor: Daiichi Sankyo

Principal Investigator, A phase lV Study to assess the safety in research participants treated with commercial ILUVIEN for diabetic macular edema, with primary focus on increased IOP. Sponsor: Alimera Paladin

Investigator, Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration. Sponsor: Allergan

Principal Investigator, A Phase III, Multicenter, Randomized, Double-Masked, Sham Treatment-Controlled Study Assessing the Safety and Efficacy of Intravitreal Injections of Sirolimus (two doses) for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye. Sponsor: Santen Sakura

Principal Investigator, A Phase III, multi-Center, Randomized, Double- Masked, Sham-Controlled Study To Assess The Efficacy and safety of Lampalizumab administered Intravitreally to patients with geographic atrophy secondary to age –related macular degeneration. Sponsor: Genentech Roche

Principal Investigator, APhase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients with Geographic Atrophy (GA). Sponsor: Apellis Filly

Investigator, A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema. Sponsor: Astellas

Investigator, Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration. Sponsor: Allergan

Principal Investigator, to demonstrate superior vitrectomy outcome with 27-gauge compare to 23-gauge instruments. Sponsor: Alcon

Investigator, A prospective, multicenter post-approval study of VisionCare’s Implantable Miniature Telescope in patients with bilateral severe to profound central vision impairment associated with end-stage age-related macular degeneration. Sponsor: VisionCare IMT

Principal Investigator, A Phase ll, Multi center Randomized, Active treatment- controlled study of the efficacy and safety of the Ranibizumab port delivery system for sustained delivery of Ranibizumab in patients with sub foveal neovascular age-related macular degeneration. Sponsor: Genentech Ladder

Investigator, A Phase II, Randomized, Double-Masked, Placebo-Controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy of Luminate in Inducing PVD in Subjects with Non-Proliferative Diabetic Retinopathy. Sponsor: Allegro

**2015**

Principal Investigator, Ophthotech OPH1005 NAÏVE and prev treated wet AMDOPH1005 sub-retinal fibrosis in Neovascular AMD; a 24-month phase 2A open label safety study of Fovista (anti-PDGF-BB Pegylated Aptamer) regimen administered independently or in combination with Anti-VEGF therapy (Avastin or EYELea) during the induction and maintenance phases of therapy.

Investigator, Ophthotech Fovista – NAÏVE AMD; Phase 3 Randomized, Double-Masked study to test safety and efficacy of Fovista anti-PDGF in combination with Lucentis vs Lucentis alone for wet AMD.

Investigator, Ophthotech NAÏVE 1004; A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ administered in combination with either Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects with subfoveal neovascular age-related macular degeneration.

Investigator, Ophthotech 2002,A phase 2a study to establish the safety and tolerability of Zimura (anti-C5 aptamer) in combination with anti-VEGF therapy in subjects with idiopathic polypoidal choroidal vasculopathy (IPCV)

Principal Investigator, A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration. Sponsor: Alcon

Principal Investigator, Observational study: will collect information about Serious Medical Events (SMEs) that occurred since the patients’ last CATT visits. This will be collected at a single return visit. Sponsor: CATT FUS

Principal Investigator, A 2-year Phase III double-masked sham controlled-assessing the efficacy and safety of Lampalizumab given intravitreally every 4 weeks or 6 weeks. Sponsor: Genentech Roche

Principal Investigator, The Ozurdex Diabetic Macular Edema (DME) Patient Registry. Sponsor: Allergan

Investigator, Pfizer DME; A phase 2, randomized, double-masked, placebo-controlled, parallel group, multicenter study to compare the efficacy and safety of a chemokine CCR2/5 receptor antagonist (PF-04634817) with that of ranibizumab in adult subjects with DME.

Investigator, SCORE2-Previous Tx and NAÏVE (CRVO); A Multicenter, Prospective Randomized phase 3, Non-Inferiority Trial of Eyes with Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab v Intravitreal Afibercept Every 4 weeks, through month 5 then Good response will go into a Treatment and Extend with 2-week extension increments Month 6 – 11, some Poor or marginal response will get Dexamethasone implant at month 6 and PRN M9, M10, M11.

Investigator, ThromboGenics ORBIT; a phase IV study of the use of commercial ocriplasmin in patients with symptomatic VMA.

Principal Investigator, DE-109 Protocol 32-007A Phase III, Multicenter, Randomized, Double-Masked, Sham Treatment-Controlled Study Assessing the Safety and Efficacy of Intravitreal Injections of Sirolimus (two doses) for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye. Sponsor: Santen Incorportated

Principal Investigator, DE-120 Protocol 35-002 OriginalA Multicenter, Randomized, Open Label, Phase IIa Study Assessing the Efficacy, Safety and Duration of Effect of Intravitreal Injections of DE-120 (a VEGF And PDGF

ReceptOR Inhibitor) as Monotherapy and with a Single Eylea® injection in Subjects with Treatment-naïve Exudative Age-related Macular Degeneration- VAPOR 1 SPONSOR: Santen Incorporated

Principal Investigator - DE-109 Protocol 32-009 SPRING OriginalA Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects with Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program SPONSOR: Santen Incorporated

**2014**

Principal Investigator, Genentech Roche GX29176; A 2 year Phase III double-masked sham controlled-assessing the efficacy and safety of Lampalizumab given intravitreally every 4 weeks or 6 weeks.

Principal Investigator, Ophthotech IST; An open label trial to investigate the safety, tolerability and development of subfoveal fibrosis by intravitreal administration of altering regimens of Fovista and Anti-VEGF therapy in subjects with neovascular AMD.

Principal Investigator, Ophthotech OPH1005 NAÏVE and prev treated wet AMD; OPH1005 sub-retinal fibrosis in Neovascular AMD; a 24 month phase 2A open label safety study of Fovista (anti-PDGF-BB Pegylated Aptamer) regimen administered independently or in combination with Anti-VEGF therapy (Avastin or Eyelea) during the induction and maintenance phases of therapy.

Investigator, Aerpio Therapeutics DME Study; A phase 2, Randomized, Active Controlled, single-masked, multi-center study to assess the safety and efficacy of daily subcutaneous AKB-9778 administered for 3 months, as monotherapy or adjunctive to ranibizumab, in subjects with DME.

Investigator, Allergan 150998-003 NAÏVE AMD; Evaluation of Abicipar Pegol (AGN-150998) in patients with Neovascular Age-Related Macular Degneration.

Investigator, Allergan 150998-004 for DME; Evaluation of Abicipar Pegol (AGN-150998) in patients with DME.

Principal Investigator, Allergan Reinforce Chart Study; The Ozurdex Diabetic Macular Edema (DME) Patient Registry.

Principal Investigator, CATT FS (CATT follow-up study); The CATT Follow-Up study (CATT FS) is an observational study. Most patients have received some type of treatment for the CNV since their last CATT visit. Recognizing that there is a need for more information on the safety effects of Lucentis, Avastin, and intravitrally delivered anti-VEGF drugs in general, the CATT FS will collect information about Serious Medical Events (SMEs) that occurred since the patients’ last CATT visits.

Principal Investigator, Covance NAION; Prospective, case crossover, non-interventional, phase IV study in subjects of adult men with ED, first diagnosed with NAION which started within 45 days before study start, and who took PDE5 inhibitors in the 1 year prior to NAION onset.

Principal Investigator, Psivida PSV-FAI-001/Uveitis; APhase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of Fluocinolone Acetonide Intravitreal (FAI) Insert in subjects with chronic non-infectious Uveitis affecting the posterior segment of the eye.

Investigator, Lpath LT1009-Oph-003 (NEXUS); MOA: Sonepcizumab/LT1009 is a recombinant, humanized, IgG1κ, biospecific monoclonal antibody that binds to S1P. sonepcizumab demonstrated profound anti-angiogenic effects. A Phase 2a, multi-center, masked, randomized, comparator-controlled study evaluating iSONEP (sonepcizumab [LT1009]) as either monotherapy or adjunctive therapy to Lucentis® or Avastin® versus Lucentis or Avastin alone for the treatment of subjects with choroidal neovascularization secondary to age-related macular degeneration.

**2013**

Principal Investigator, A Phase 2b/3 Randomized, Double-Masked, Dose-Ranging, Multicenter Study Comparing the Efficacy and Safety of ACU-4429 with Placebo for the Treatment of Geographic Atrophy Associated with Dry Age-Related Macular Degeneration (S.E.A.T.T.L.E.) (4429-202), sponsored by Acucela

Principal Investigator, A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 versus EYLEA® in Subjects with Exudative Age-Related Macular Degeneration (OSPREY) (C-12-006), sponsored by Alcon

Principal Investigator, A multicenter, open-label, single ascending dose study to assess the safety, tolerability, and serum pharmacokinetics of intravitreal CLG561 in subjects with advanced age-related macular degeneration (C-12-074), sponsored by Alcon

Principal Investigator, A clinical trial to assess the impact of home monitoring to decrease the treatment burden for Neovascular Macular Degeneration (the LIBERTY study) (ML28727). An Investigator-sponsored trial.

Investigator, Phase 3 Randomized, Double-Masked study to test safety and efficacy of Fovista anti-PDGF in combination with Lucentis vs Lucentis alone for wet AMD (OPH1002), sponsored by Ophthotech.

Principal Investigator, A Prospective, Two Cohort, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects with Exudative Age-Related Macular Degeneration (C-13-001), sponsored by Alcon.

Principal Investigator, MOA: Acucela GA study;modulates the enzymatic phototransduction pathway.

Principal Investigator, Alcon C-12-074 – advanced AMD (NV or GA); A multicenter, open label, single ascending dose study to assess the safety, tolerability, and serum pharmacokinetics of intravitreal administration of CLG561 to subjects with advanced age-related macular degeneration.

Principal Investigator, Alcon C-13-001 NAÏVE AMD; A Prospective, Two Cohort, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Micro Volume Injection or Infusion in Subjects with Exudative Age-Related Macular Degeneration; Alcon C-13-001 Extension Study; Extension of the micro volume infusion study; regulatory document submission to begin soon

Principal Investigator, Allergan IST; A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX Intraocular Implant in Patients with Diabetes Mellitus Who Developed Macular Edema After Cataract Surgery

Principal Investigaor, Allergan RVO/DME Chart Review Study; This study will give retrospective data to assess if at any point during the study patients are getting to a certain point on BCVA and mean central subfield thickness with at least 3 anti-VEGF injections in the treatment of macular edema due to RVO or DME.

Principal Investigator, Genentech LIBERTY IST; A clinical trial to assess the impact of home monitoring to decrease the treatment burden for Neovascular Macular Degeneration.

Investigator, Ophthotech OPH1002 Fovista – NAÏVE AMD; Phase 3 Randomized, Double-Masked study to test safety and efficacy of Fovista anti-PDGF in combination with Lucentis vs Lucentis alone for wet AMD.

Principal Investigator, A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients with Neovascular Age-related Macular Degeneration. LFG316A2201, sponsored by Novartis

Principal Investigator, Safety Assessment and Therapeutic Effect of Non-Damaging Patterned Scanning Laser Phototherapy in Patients with Diffuse Diabetic Macular Edema (Topcon2012). An Investigator-sponsored trial.

**2012**

Investigator, A Phase 2a, Multicenter, Masked, Randomized, Comparator-Controlled Study Evaluating iSONEP (sonepcizumab [LT1009]) As Either Monotherapy or Adjunctive Therapy to Lucentis®or Avastin® Versus Lucentis or Avastin Alone for the Treatment of Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Lpath LT1009-Oph-003, sponsored by Lpath

Principal Investigator, A 3-Month Clinical Trial to Assess the Safety and Efficacy of the Ozurdex® Intraocular Implant in Patients with Diabetes Mellitus Who Developed Macular Edema After Cataract Surgery. An Investigator-sponsored trial.

Principal Investigator, Novartis CLFG316A2203 for GA; MOA: LFG316 is a recombinant, high-affinity, human monoclonal antibody of the IgG1/lambdaisotype, directed against the fifth component (C5) of the human complement cascade. A multicenter, randomized, sham-control, single masked, proof-of-concept study of intravitreal LFG316 in patients with geographic atrophy associated with age-related macular degeneration

Principal Investigator, Santen 32-007 for Uveitis; A Phase III, Multicenter, Randomized, Double-Masked, Sham Treatment-Controlled Study Assessing the Safety and Efficacy of Intravitreal Injections of Sirolimus (two doses) for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye.

Principal Investigator, A Multicenter, Randomized, Single-Masked, Sham-Controlled, Proof-Of-Concept Study of Intravitreal AL-78898A In Patients with Bilateral Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD) (C-12-020), sponsored by Alcon.

An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined with A Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating The Efficacy and Safety of PF-04523655 Alone and in Combination with Ranibizumab Versus Ranibizumab Alone in Diabetic Macular Edema (MATISSE) (QRK202), sponsored by Quark Pharmaceuticals, Inc.

Principal Investigator, A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination with Bevacizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema with Involvement of FoveAL Center (iDEAL) (2010007-03-DME), Investigator- Sponsored Trial

Principal Investigator, A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (VIBRANT) (VGFTe-RVO-1027), sponsored by Regeneron.

**2011**

Investigator, CRAVE: CompaRison of Anti-VEGF agents in the treatment of macular edema from retinal VEin occlusion, Investigator-Sponsored Trial.

Investigator, Single Dose Study of the Safety and Efficacy of AGN-150998 in Patients with Exudative Age-related Macular Degeneration (REACH) (150998-001), sponsored by Allergan.

Principal Investigator, A Randomized, Sham-Controlled, Double-Masked, Multicenter Trial Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) (TG-MV-014), sponsored by ThromboGenics.

Principal Investigator, A multicenter, randomized, sham-control, proof-of-concept study of intravitreal LFG316 in patients with geographic atrophy associated with age-related macular degeneration (CLFG316A2203), sponsored by Novartis.

Investigator, A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients With Diabetic Macular Edema (206207-024), sponsored by Allergan.

Investigator, GSK BAM114341 GA; MOA: murine humanised anti-human beta amyloid (A) immunoglobulin 1 (IgG1) monoclonal antibody (mAb), GSK933776 binds with high affinity to A (both 1 to 40 and 1 to 42) and is believed to act by a postulated “peripheral sink‟ mode of action resulting in an overall shift of A from the brain or eye into the plasma compartment.

Principal Investigator, A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (1% and 2%) Twice daily for the Treatment of Center-involving Clinically Significant Macular Edema Associated with Diabetic Retinopathy (FOV2304/CLIN/201/P), sponsored by FOVEA Pharmaceutical SA.

Principal Investigator, A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye (SAKURA) (32-007), sponsored by Santen.

Investigator, A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (VISTA) (VGFT-OD-1009), sponsored by Regeneron.

Principal Investigator, Safety and Efficacy Study of ESBA1008 versus LUCENTIS® for the Treatment of Exudative Age-Related Macular Degeneration (SEE) (C-10-083), sponsored by Alcon.

Investigator, A phase 2, multi-center, randomised, double-masked, placebo-controlled, parallel-group study to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (BAM114341), sponsored by GlaxoSmithKline.

Principal Investigator, Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects with Dry Age-Related Macular Degeneration (Geographic Atrophy) (4429-201), sponsored by Acucela, Inc.

Investigator, A Multi-center, Double-Masked, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Noninfectious Intermediate, Posterior or Pan-uveitis (LX211-11), sponsored by Lux Biosciences, Inc.

Principal Investigator, A multicenter, open label, single ascending dose study to assess the safety, tolerability, and serum pharmacokinetics of intravitreal LFG316 in patients with advanced age-related macular degeneration (LFGJ316A2102), sponsored by Novartis.

Investigator, A Phase I, Open-label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients with Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II) (QRK.007), sponsored by Quark Pharmaceuticals, Inc.

**2010**

Principal Investigator, Prospective Case Crossover Study to Assess Whether PDE5 Inhibitor Exposure in Men with Erectile Dysfunction Increases the Risk for Development of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) (12912), sponsored by Bayer Healthcare AG.

Principal Investigator, A Phase I, Open-Label, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAV2-sFLT01 in Patients with Neovascular Age-Related Macular Degeneration (sFLT01-AMD-00106), sponsored by Genzyme Corporation.

Principal Investigator, A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate-, Posterior-, or Pan-uveitis (M10-877), sponsored by Abbott Laboratories.

Principal Investigator, A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis (M10-880), sponsored by Abbott Laboratories.

Principal Investigator, A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Non-infectious Intermediate-, Posterior-, or Pan-uveitis (M11-327), sponsored by Abbott Laboratories.

Investigator, A Phase I, 12-Month, Multicenter, 2-Stage (Open-Label, Dose-Escalation, Followed by Masked, Randomized) Single Dose Study of the Safety and Efficacy of AGN-208397 (beclomethasone dipropionate intravitreal injection) in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO) (208397-001), sponsored by Allergan.

Investigator, A 12-Month, Multicenter, Masked, Randomized, Controlled Study to Assess the Safety and Efficacy of 700µg Ozurdex® (700µg Dexamethasone) as Adjunctive Therapy to Lucentis® Compared to Lucentis® Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (206207-021), sponsored by Allergan.

Principal Investigator, An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage due to Proliferative Diabetic Retinopathy (Protocol N), sponsored by the National Eye Institute.

Principal Investigator, A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Study Medication Given in Combination with Lucentis® in Subjects with Neovascular Age-Related Macular Degeneration (OPH1001), sponsored by Ophthotech.

Principal Investigator, A Phase 2b Dose-Finding Study of Study Medication versus Ranibizumab Injections for the Treatment of Neovascular Age-Related Macular Degeneration (MD7110852), sponsored by GlaxoSmithKline.

Co-Primary Investigator, A Multicenter, Masked, Randomized, Sham-Controlled, Parallel-Group, 3 Month Study with a 9-Month Safety Extension to Evaluate the Safety and Efficacy of Study Medication in Improving Visual Function in Patients with a Previous Rhegmatogenous Macula-Off Retinal Detachment (190342-031D), sponsored by Allergan.

**2009**

Principal Investigator, A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Study Medication in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (COPERNICUS) (VGFT-OD-0819), sponsored by Regeneron.

Principal Investigator, A randomized, double-masked, placebo-controlled, add-on study to assess the efficacy of Study Medication once daily for diabetic macular edema (CSPP100A2244), sponsored by Novartis.

Co-Primary Investigator, A 26-Week, Open Label Study to Assess the Safety and Efficacy of Study Medication as Adjunctive Therapy to Lucentis® in the Treatment of Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (206207-019), sponsored by Allergan.

Co-Primary Investigator, A Randomized, Placebo Controlled, Double-Masked, Multicenter Trial of Study Medication for Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion Trial (TG-MV-006), sponsored by ThromboGenics.

Co-Primary Investigator, A 26-Week, Open-Label Study to Assess the Safety and Efficacy of Study Medication in the Treatment of Vitrectomized Subjects with Diabetic Macular Edema Trial (206207-018) sponsored by Allergan.

**2008**

Co-Primary Investigator, A Phase 2, Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of Lucentis® plus Study Medication versus Lucentis® plus Placebo in Patients with Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD-003), sponsored by MacuSight.

Principal Investigator, An Open-Label, Ocular Safety and Tolerance Study to Compare Various Configurations of The Study Device in Patients Undergoing Sutureless Vitrectomies (OPK-02-101), sponsored by Opko.

Principal Investigator, An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability Of Study Medication In Subjects With Choroidal Neovascularization (CNV) Secondary To Age-Related Macular Degeneration (AMD) of Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed A Genentech-Sponsored Study Medication Study (FVF3426g Cohort 2), sponsored by Genentech.

Co-Primary Investigator, A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age-Related Macular Degeneration in Patients that Require Persistent Anti-VEGF Therapy (NVI-008), sponsored by NeoVista.

Co-Primary Investigator, A Phase 1, Dose-Escalating, Multi-Center, Study of Study Medication Administered as an Intravitreal Injection to Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (LT1009-Oph-001), sponsored by Lpath.

Co-Primary Investigator, A Phase II, Prospective, Randomized, Multi-Center, Diabetic Macular Edema Dose Ranging, Comparator Study Evaluating The Efficacy and Safety of Study Medication Versus Laser Therapy (B0451004), sponsored by Pfizer, Inc.

Principal Investigator, A Prospective, Pilot Study of the PASCAL® (Pattern Scan Laser) for the Treatment of Clinically Significant Macular Edema in patients with Non-Proliferative Diabetic Retinopathy (PARS-1-508), sponsored by Pascal.

Co-Primary Investigator, A Phase ½, Randomized Clinical Study to Assess the Safety and Efficacy of Study Medication in Patients with Newly Diagnosed, Treatment Naiive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD-002), sponsored by MacuSight.

Co-Primary Investigator, A Multicenter, Masked, Randomized, Sham-controlled, Paired-eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Study Medication in Patients with Geographic Atrophy from Age-related Macular Degeneration (190342-032D), sponsored by Allergan.

Co-Primary Investigator, A Randomized, Double-Masked, Dose-Ranging, Multi-Center, Phase II study Comparing the Safety and Efficacy of Study Medication with Placebo to Treat Geographic Atrophy associated with Age-Related Macular Degeneration (OT-551-C04), sponsored by Othera Pharmaceuticals.

Co-Primary Investigator, A Phase III Safety and Efficacy Study of Vitresolve® for Ophthalmic Intravitreal Injection for Inducing Posterior Vitreous Detachment in Retinopathy Subjects (PVD-301), sponsored by Vitreoretinal Technologies, Inc.

Co-Primary Investigator, A Phase II randomized, double-masked, study to evaluate the safety and prelinimary efficacy of Study Medication in patiens with neovascular AMD receiving maintenance intravitreal anti-VEGF antibody therapy (Lucentis® or Avastin®) (ATG003-203), sponsored by CoMentis.

Co-Primary Investigator, A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Study Medication in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy (DR-002), sponsored by MacuSight.

Co-Primary Investigator, A 6-Month, Single-Masked, Multicenter, Randomized, Controlled Study to Assess the Safety and Efficacy of Study Medication as Adjunctive Therapy to Lucentis® Compared with Lucentis® Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (206207-016), sponsored by Allergan.

Co-Primary Investigator, A Phase I, Open-Label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability of Study Medication in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy (NVG07D108), sponsored by Novagali.

Co-Primary Investigator, A Phase III, Randomized, Double-Masked, Parallel-Assignment Study of Study Medication administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis® compared with Lucentis® monotherapy every 4 weeks in patients with Exudative Age-Related Macular Degeneration (ACU301) sponsored by Opko.

Co-Primary Investigator, A 52-Week, Masked, Multicenter, Randomized, Controlled Trial to Assess the Safety and Efficacy of 700µg Study Medication in Combination with Laser Photocoagulation Compared with Laser Photocoagulation Alone in the Treatment of Subjects with Diffuse Diabetic Macular Edema (206207-012), sponsored by Allergan.

Principal Investigator, A Phase IIB, Randomized, Masked, Sham-Controlled, Clinical Trial to Study the Efficacy and Safety of the Study Medication in Diabetic Patients with Clinically Significant Macular Edema (MK0140), sponsored by Merck.

**2007**

Co-Primary Investigator, Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion Trial (9633-SCORE) sponsored by the National Eye Institute.

Principal Investigator, A Phase III, Double-Masked, Multi-Center, Randomized, Sham-Controlled Study of the Efficacy and Safety of Study Medication in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus (FVF4170g), sponsored by Genentech, Inc.

Principal Investigator, A Phase III, Multi-Center, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Study Medication Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion (FVF4165g), sponsored by Genentech, Inc.

Principal Investigator, A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Study Medication Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (FVF4166g), sponsored by Genentech, Inc.

Principal Investigator, Comparison of Age-Related Macular Degeneration Treatments Trial (CATT), sponsored by the National Eye Institute.

Co-Primary Investigator, A Randomized, Prospective, Active Controlled Study of The NeoVista Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age-Related Macular Degeneration (NVI-114-003) sponsored by NeoVista, Inc.

Principal Investigator, A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal Study Medication in Subjects with Neovascular Age-Related Macular Degeneration (VGFT-OD-0605) sponsored by Regeneron.

Co-Primary Investigator, Open Label Treatment for Patients Completing Study B7A-MC-MBCM (B7A-MC-MBDV) sponsored by Eli Lilly.

Co-Primary Investigator, A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of Study Drug in Patients with Neovascular Age-Related Macular Degeneration Trial (VGFT-OD-0508) sponsored by Regeneron.

**2006**

Principal Investigator, A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study to Assess the Efficacy and Safety of Study Medication as Therapy in Subjects with Active Sight Threatening, Non-Infectious, Intermediate-, Anterior, and Intermediate-, Posterior-, or Pan-Uveitis (LX211-01-UV), sponsored by Lux Biosciences, Inc.

Principal Investigator, A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study to Assess the Efficacy and Safety of Study Medication as Therapy in Subjects with Clincially Quiescent Sight Threatening, Non-Infectious, Intermediate-, Anterior, and Intermediate-, Posterior-, or Pan-Uveitis (LX211-02-UV), sponsored by Lux Biosciences, Inc.

Co-Primary Investigator, A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel Group Evaluation of the Safety and Efficacy of Study Medication to Prevent Formation or Delay Progression of Nuclear Cataract Formation in Post-Vitrectomy Patients (OT-551-002), sponsored by Othera Pharmaceuticals, Inc.

Principal Investigator, RHEO-AMD, Safety and Effectiveness in a Multi-center, Randomized, Sham-controlled Investigation for Age-Related Macular Degeneration (AMD) Using the Rheophoresis Treatment Trial (RHEO-AMD 01-06) sponsored by OccuLogix, Inc.

Principal Investigator, Double-Masked, Placebo-Controlled, Multi-Center, Dose-Ranging Study to Assess the Efficacy and Safety of Study Medication as Therapy in Subjects with Active Sight Threatening, Non-Infectious Anterior Uveitis (LX211-03-UV), sponsored by Lux Biosciences, Inc.

Principal Investigator, Study Medication for Edema of the Macula in Diabetes: A Phase 2 Study (READ-2), Investigator-Sponsored Trial.

Co-Primary Investigator, A 2-Year, Multi-Center, Randomized, Controlled, Masked, Dose-Finding Trial to Assess the Safety and Efficacy of Multiple Injections of Study Medication in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (211745-001-00), sponsored by Allergan.

Principal Investigator, Study Medication for the Treatment of Serous Pigment Epithelial Detachment due to Age-Related Macular Degeneration (FVF3538s), sponsored by Retinal Consultants of Arizona, Ltd.

Co-Primary Investigator, A Randomized, Double-Masked, Parallel Group, Multicenter, Dose-Finding Comparison of the Safety and Efficacy of Study Medication to Sham Injection In Subjects with Diabetic Macular Edema (C-01-05-001), sponsored by Alimera Sciences, Inc. and Sivida, Inc.

Principal Investigator, A Phase I, Open-Label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability of Study Medication in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy (DR-001) sponsored by MacuSight, Inc.

Principal Investigator, A Phase I, Randomized, Open-Label, Dose-Escalation Clinical Study to Assess The Safety and Tolerability of Study Medication in Patients with Newly Diagnosed, Treatment-Naïve Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD-001.02), sponsored by MacuSight, Inc.

**2005**

Co-Primary Investigator, An Evaluation of Efficacy and Safety of Study Medication combined with Transpupillary Thermotherapy (TTT) in Patients with Subfoveal Exudative Age Related Macular Degeneration (AMD) (2005-0553) sponsored by Retinal Consultants of Arizona, Ltd.

Principal Investigator, A Prospective, Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Tolerability of Two Dose Levels of the Study Medication In Diabetic Macular Edema (HITI-001), sponsored by SurModics.

Co-Primary Investigator, An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Study Medication in Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Who Have Completed the Treatment Phase of a Genentech-Sponsored Trial (FVF3426g), sponsored by Genentech, Inc.

Co-Primary Investigator, A Phase IIIB, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Study Medication in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (FVF3689g), sponsored by Genentech, Inc.

Co-Primary Investigator, A Phase IIIB/IV, Randomized, Active Controlled, Double-Masked, Single Dummy, Multi-Center Study Comparative Trial, in Parallel Groups, to Compare the Safety and Efficacy of Study Medication Given Every 6 Weeks for up to 102 Weeks Plus Sham Photodynamic Therapy (PDT), to Study Medication Plus PDT, in Subjects with Predominantly Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (EOP1012C), sponsored by Eyetech, Inc.

Co-Primary Investigator, A Phase II, Randomized, Double-Masked, Controlled, Dose Comparison Study of Intravitreal Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age-Related Macular Degeneration (ACU-201), sponsored by Acuity Pharmaceuticals.

Co-Primary Investigator, A Phase II, Pharmacokinetic, Randomized, Double-Masked, Controlled, Dose Comparison Study of Intravitreal Injection for the Treatment of Diabetic Macular Edema (ACU211), sponsored by Acuity Pharmaceuticals.

**2004**

Principal Investigator, An Evaluation of Efficacy and Safety of Posterior Juxtascleral Administrations of Study Medication for Depot Suspension (15mg or 30mg) Versus Sham Administration in Patients (Enrolled in Study “A” or Study "B”) at Risk for Developing Sight-Threatening Choroidal Neovascularization Due to Exudative Age-Related Macular Degeneration (C-02-60), sponsored by Alcon.

Co-Primary Investigator, a Six-Month, Phase III, Multi-Center, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open Label Extension) to Assess the Safety and Efficacy of Study Medication in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion (206207-009), sponsored by Allergan.

Co-Primary Investigator, A Phase II, Randomized, Masked, Single and Multiple Dose, Sequential Dose-Escalation Study of the Safety and Efficacy of Study Medication in Subjects with Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration (A4321001), sponsored by Pfizer, Inc.

Co-Primary Investigator, A Phase II, Multi-Center, Randomized, Masked, Controlled Study of the Effects of Study Medication in Combination with Visudyne® in Patients with Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration (MSI-126F-208), sponsored by Genaera

Co-Primary Investigator, A Phase II, Multi-Center, Randomized, Masked, Controlled Study for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age Related Macular Degeneration (MSI-126F-209), sponsored by Genaera

Co-Primary Investigator, A Phase II, Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial in Parallel Groups to Determine the Safety, Efficacy and Pharmacokinetics of Study Medication Compared to Sham Injections for 30 Weeks in Patients with Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (EOP1011C), sponsored by Eyetech, Inc.

**2003**

Co-Primary Investigator, A Phase III, Multi-Center, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Study Medication in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age Related Macular Degeneration (FVF2598g), sponsored by Genentech, Inc.

**2002**

Co-Primary Investigator,A Phase I/II, Single-Masked, Multi-Center Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Study Medication in Combination with Verteporfin (Visudyne®) Photodynamic Therapy in Subjects with Neovascular Age-Related Macular Degeneration Trial (FVF2428g) sponsored by Genentech, Inc.

**2001**

Principal Investigator, A Phase II, Randomized, Multi-Center, Dose-Ranging, Controlled Parallel Group Trial to Assess Safety and Efficacy of Study Medication in the Treatment of Persistent Macular Edema (CD103-06-02), sponsored by Oculex.

Co-Primary Investigator, A Phase II/III, Randomized, Double Masked, Controlled, Dose-Ranging, Multi-Center, Comparative Trial in Parallel Groups, to Compare the Safety and Efficacy of Study Medication Given Every Six Weeks in Patients with Exudative Age Related Macular Degeneration (EOP1004C) sponsored by Eyetech, Inc.

Principal Investigator, A Multi-Center, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of Study Medication in the Treatment of Patients with Diabetic Macular Edema (CDS FL-007), sponsored by Control Delivery Systems.

Co-Primary Investigator, A Multi-Center, Randomized, Masked, Controlled Study to Evaluate Study Medication in Patients with Diabetic Macular Edema (CDS FL-005), sponsored by Control Delivery Systems.

Co-Primary Investigator, Diabetic Retinopathy Study 2. A Phase III Clinical Trial (B7A-MC-MBCM), sponsored by Eli Lilly.

Co-Primary Investigator, Basal Laminar Drusen Trial (BLD), sponsored by the National Eye Institute.

**2000**

Principal Investigator, A Multicenter, Randomized, Double Masked, Controlled Study to Evaluate the Safety and Efficacy of Study Medication in Patients with Non-Infectious Uveitis Affecting the Posterior Segment of the Eye (415-001), sponsored by Bausch + Lomb.

**1999**

Co-Primary Investigator, Complications of Age-Related Macular Degeneration Prevention Trial (CAPT), sponsored by the National Eye Institute

Co-Primary Investigator, Submacular Surgery Trial (SST), sponsored by the National Eye Institute

**Patents**

**1993**

Sadun, AA, Dugel PU, Gill PS: Pentoxiphylline in the treatment of AIDS associated optic neuopathy and related AIDS associated disorders

**Peer Reviewed Journals**

**2018**

***Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA.***

Yu TM, **Dugel PU,** Haller JA, Kaiser PK, Arnold RJ. J Comp Eff Res. 2018 Oct 23. doi: 10.2217/cer-2018-0057.

***Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis.***

Kiss S, **Dugel PU**, Khanani AM, Broder MS, Chang E, Sun GH, Turpcu A. Clin Ophthalmol. 2018 Aug 30; 12:1625-1635. doi: 10.2147/OPTH.S169143.

***Real-World Assessment of Dexamethasone Intravitreal Implant in DME: Findings of the Prospective, Multicenter REINFORCE Study.*** Singer M, **Dugel P,** Fine H, Capone A, Maltman J. Real-World Assessment of Dexamethasone Intravitreal Implant in DME: Findings of the Prospective, Multicenter REINFORCE Study. Ophthalmic Surg Lasers Imaging Retina. 2018 June 21; 49: 425-435. doi: 10.3928/23258160-20180601-07

***Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial.*** *Rosenfeld PJ,****Dugel PU****, Holz FG, Heier JS, Pearlman JA, Novack RL, Csaky KG, Koester JM, Gregory JK, Kubota R. Ophthalmology. 2018 Apr 28. pii: S0161-6420(17)33878-2. doi: 10.1016/j.ophtha.2018.03.059. [Epub ahead of print] PMID: 29716784*

***Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2).*** Jumper JM, **Dugel PU**, Chen S, Blinder KJ, Walt JG. Clin Ophthalmol. 2018 Apr 3; 12:621-629. doi: 10.2147/OPTH.S163859. eCollection 2018. PMID: 29662298

***Association Between Early Anatomic Response to Anti-Vascular Endothelial Growth Factor Therapy and Long-Term Outcome in Diabetic Macular Edema: An Independent Analysis of Protocol I Study Data.*****Dugel PU**, Campbell JH, Kiss S, Loewenstein A, Shih V, Xu X, Holekamp NM, Augustin AJ, Ho AC, Gonzalez VH, Whitcup SM. Retina. 2018 Feb 22. doi: 10.1097/IAE.0000000000002110

**2017**

***THE OASIS MP-1 SUBSTUDY: Characterization of the Effect of Ocriplasmin on Microperimetry Parameters.***

Sadda SR, **Dugel PU,** Gonzalez VH, Meunier E, Kozma P. Retina. 2017 Dec 4. doi: 10.1097/IAE.0000000000001982.

***Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set.*** Lotery A, Griner R, Ferreira A, Milnes F, **Dugel P**. Eye (Lond). 2017 Dec;31(12):1697-1706. doi: 10.1038/eye.2017.143. Epub 2017 Jul 21.

***Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial*. Dugel PU**, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, Singerman L.

Ophthalmology. 2017 May 24. pii: S0161-6420(16)32413-7. doi: 10.1016/j.ophtha.2017.03.057. [Epub ahead of print] PMID: 28551167

***Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial.*** Heier JS, Kherani S, Desai S, **Dugel P**, Kaushal S, Cheng SH, Delacono C, Purvis A, Richards S, Le-Halpere A, Connelly J, Wadsworth SC, Varona R, Buggage R, Scaria A, Campochiaro PA.

Lancet. 2017 May 17. pii: S0140-6736(17)30979-0. doi: 10.1016/S0140-6736(17)30979-0. [Epub ahead of print]

PMID: 28526489

***Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1).*** Blinder KJ, **Dugel PU**, Chen S, Jumper JM, Walt JG, Hollander DA, Scott LC. Clin Ophthalmol. 2017 Feb 21;11:393-401. doi: 10.2147/OPTH.S128509. eCollection 2017.PMID: 28260851

***CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA.*** Chakravarthy U, Yang Y, Lotery A, Ghanchi F, Bailey C, Holz FG, Downey L, Weber M, Eter N, **Dugel PU**. Retina. 2017 Mar 13. doi: 10.1097/IAE.0000000000001555. [Epub ahead of print] PMID: 28257378

***Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial.*** Jaffe GJ, Ciulla TA, Ciardella AP, Devin F, **Dugel PU**, Eandi CM, Masonson H, Monés J, Pearlman JA, Quaranta-El Maftouhi M, Ricci F, Westby K, Patel SC. Ophthalmology. 2017 Feb;124(2):224-234. doi: 10.1016/j.ophtha.2016.10.010. Epub 2016 Oct 28. PMID: 28029445

***SCORE2 Report 2: Study Design and Baseline Characteristics.*** Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Figueroa M, **Dugel PU**; SCORE2 Investigator Group. Ophthalmology. 2017 Feb;124(2):245-256. doi: 10.1016/j.ophtha.2016.09.038.

**2016**

***Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice,*** Jeffrey S. Heier, MD; Neil M. Bressler, MD; Robert L. Avery, MD; Sophie J. Bakri, MD; David S. Boyer, MD; David M. Brown, MD; **Pravin U. Dugel**, MD; K. Bailey Freund, MD; Adam R. Glassman, MS; Judy E. Kim, MD; Daniel F. Martin, MD; John S. Pollack, MD; Carl D. Regillo, MD; Philip J. Rosenfeld, MD, PhD; Andrew P. Schachat, MD; John A. Wells III, MD, JAMA Ophthalmology, 2016; 134 (1): 95-99. doi: 10.1001/jamaophthalmol.2015.4110

***Early and Long-term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data***. Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, Ma J, Ho AC, Patel V, Whitcup SM, **Dugel PU**.

***Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study***. Sarraf D, London NJ, Khurana RN, **Dugel PU**, Gune S, Hill L, Tuomi L – Ophthalmology 2016

***Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin****.* Jackson TL, Regillo CD, Girach A, **Dugel PU**; MIVI-TRUST Study Group - Ophthalmic Surgical Lasers Imaging Retina. 2016

***Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.*** **Dugel PU,** Tolentino M, Feiner L, Kozma P, Leroy A. Ophthalmology. 2016

***Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials****.* **Dugel PU,** Hillenkamp J, Sivaprasad S, Vögeler J, Mousseau MC, Wenzel A, Margaron P, Hashmonay R, Massin P. Clinical Ophthalmology. 2016

***Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.*** Campochiaro PA, Khanani A, Singer M, Patel S, Boyer D, **Dugel P**, Kherani S, Withers B, Gambino L, Peters K, Brigell M; TIME-2 Study Group. Ophthalmology. 2016

***8 Questions with OSLIR*.** **Dugel PU**. Ophthalmic Surgical Lasers Imaging Retina. 2016

***Diabetic Macular Edema Diagnosis and Treatment in the Real World: An Analysis of Medicare Claims Data (2008 to 2010).*** **Dugel PU.** Ophthalmic Surgical Lasers Imaging Retina. 2016

***Reply to 'Comments on Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants'.*** Yang Y, Bailey C, Holz FG, Eter N, Weber M, Baker C, Kiss S, Menchini U, Ruiz Moreno JM, **Dugel P**, Lotery A; FAME study group. Eye (Lond) 2016

***Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study.*** Frank G. Holz, MD, FEBO, **Pravin U. Dugel, MD**, Georges Weissgerber, MD, Robin Hamilton, MB BS DM (dist), FRCOphth, Rufino Silva, MD, PhD, Francesco Bandello, MD, FEBO, Michael Larsen, MD, DMSc, Andreas Weichselberger, PhD, Andreas Wenzel, PhD, Anne Schmidt, PhD, Dominik Escher, PhD, Laura Sararols, MD, Eric Souied, MD, PhD Ophthalmology. 2016

***Imaging of Melanin Disruption in Age-Related Macular Degeneration Using Multispectral Imaging.***

**Dugel PU,** Zimmer CN. Ophthalmic Surgical Lasers Imaging Retina. 2016

***Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.*** Souied EH, **Dugel PU,** Ferreira A, Hashmonay R, Lu J, Kelly SP. Ophthalmic Epidemiol. 2016

***Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Randomized controlled trial***. Sharma S, et al. Collaborator, **Dugel, P.** Ophthalmology. 2016

***Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.*** Randomized controlled trial; Shah N, et al, Collaborator, **Dugel, P**. Ophthalmology. 2016

***Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).*** Randomized controlled trial; Daniel E, et al, Collaborator, **Dugel, P**. Ophthalmology. 2016

***Improving Outcomes for Patients With Diabetic Macular Edema****.* Puliafito CA, **Dugel PU,** Cousins SW, Packo KH, Eaton AM, Parrish RK 2nd, Kiss S, Reichel E. Ophthalmic Surgical Lasers Imaging Retina. 2015

***Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.*** Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, **Dugel PU**, Freund KB, Glassman AR, Kim JE, Martin DF, Pollack JS, Regillo CD, Rosenfeld PJ, Schachat AP, Wells JA 3rd JAMA Ophthalmol. 2016

***Outcomes of 27 Gauge Microincision Vitrectomy Surgery for Posterior Segment Disease.***

Khan MA, Shahlaee A, Toussaint B, Hsu J, Sivalingam A, **Dugel PU**, Lakhanpal RR, Riemann CD, Berrocal MH, Regillo CD1, Ho AC. Am J Ophthalmology. 2016

**2015**

***Neovascular AMD: Where do we go from here?*** Barakat MR, **Dugel PU**. Nepal J Ophthalmol. 2015

***Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants*.** Yang Y, Bailey C, Holz FG, Eter N, Weber M, Baker C, Kiss S, Menchini U, Ruiz Moreno JM, **Dugel P**, Lotery A; 2015

***COMPARISON OF ATTRACTION CAPABILITIES ASSOCIATED WITH HIGH-SPEED, DUAL-PNEUMATIC VITRECTOMY PROBES.*** **Dugel PU,** Abulon DJ, Dimalanta R. Retina. 2015 Jan 23. [Epub ahead of print] PMID: 25621945

***Macular EpiRetinal brachytherapy in Treated AGE- related macular degeneration: MERITAGE 24 month safety and efficacy results*.** Petrarca R, **Dugel PU**, Bennett M, Barak A, Weinberger D, Nau J, Jackson TL.

***Dexamethasone intravitreal implant in the treatment of diabetic macular edema*.** Review article; **Dugel PU**, et al. Clin Ophthalmol. 2015

***Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials.***

Randomized controlled trial; Willoughby AS, et al, Collaborator, **Dugel, P**. Ophthalmology. 2015

***Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants.*** Randomized controlled trial; Yang Y, Bailey C, Holz FG, Eter N, Weber M, Baker C, Kiss S, Menchini U, Ruiz Moreno JM, **Dugel P**, Lotery A, Eye (Lond). 2015

***Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial. Randomized controlled trial****;* Kuppermann BD, Collaborator, **Dugel, P**. Ophthalmologica. 2015

***Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15.*** Randomized controlled trial; Aref AA, Collaborator, **Dugel, P**. JAMA Ophthalmol. 2015

***Phase ii, randomized, placebo-controlled, 90-day study of emixustat hydrochloride in geographic atrophy associated with dry age-related macular degeneration. Randomized controlled trial***; **Dugel PU**, Novack RL, Csaky KG, Richmond PP, Birch DG, Kubota R. Retina. 2015

***Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study.*** Randomized controlled trial. Singer MA, Capone A Jr, **Dugel PU,** Dreyer RF, Dodwell DG, Roth DB, Shi R, Walt JG, Scott LC, Hollander DA; SHASTA Study Group. BMC Ophthalmol. 2015 Apr 1;15:33. doi: 10.1186/s12886-015-0018-y

***Characterization of Anatomic and Visual Function Outcomes in Patients With Full-Thickness Macular Hole in Ocriplasmin Phase 3 Trials.*** Randomized controlled trial; **Dugel PU,** Regillo C, Eliott D. Am J Ophthalmology. 2015

***Safety Profile of Ocriplasmin for Symptomatic Vitreomacular Adhesion: A Comprehensive Analysis of Premarketing and Post Marketing Experiences.*** Hahn P, Chung MM, Flynn HW Jr., Huang SS, Kim JE, Mahmoud TH, Sadda SR, **Dugel PU**. Retina. 2015.

***Comparison of attraction capabilities associated with high-speed, dual-pneumatic vitrectomy probes***. **Dugel PU**, Abulon DJ, Dimalanta R. Retina. 2015

***Postmarketing Analysis of Aflibercept-Related Sterile Intraocular Inflammation*.** Hahn P, Chung MM, Flynn HW Jr, Huang SS, Kim JE, Mahmoud TH, Sadda SR, **Dugel PU**. JAMA Ophthalmology. 2015 Jan 15

**2014**

***Intravitreal injection technique and monitoring: updated guidelines of an expert panel.***

Avery RL, Bakri SJ, Blumenkranz MS, Brucker AJ, Cunningham ET Jr, DʼAmico DJ, **Dugel PU**, Flynn HW Jr, Freund KB, Haller JA, Jumper JM, Liebmann JM, McCannel CA, Mieler WF, Ta CN, Williams GA. Retina. 2014 Dec

***Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.*** Randomized controlled trial; Csaky KG, **Dugel PU,** Pierce AJ, Fries MA, Kelly DS, Danis RP, Wurzelmann JI, Xu CF, Hossain M, Trivedi T. Ophthalmology. 2015

***Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).*** Randomized controlled trial; Altaweel MM, Collaborator, **Dugel, P**. Ophthalmology. 2015

***Individualized, spectral domain-optical coherence tomography-guided facedown posturing after macular hole surgery: minimizing treatment burden and maximizing outcome.*** Yamashita T1, Sakamoto T, Yamashita T, Sonoda S, Yamakiri K, Otsuka H, Hisatomi T, Imaki H, Ishibashi T, **Dugel PU.** Retina. 2014

***Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema.*** Randomized controlled trial; Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, **Dugel PU**, Holz FG, Weber M, Danis RP, Kuppermann BD, Bailey C, Billman K, Kapik B, Kane F, Green K; Ophthalmology 2014

***Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials.*** Randomized controlled trial; Folgar FA, Jaffe GJ, Ying GS, Maguire MG, Toth CA Collaborator, **Dugel, P**. Ophthalmology. 2014

***Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).***

Randomized controlled trial; Kim BJ, Kim BJ, Ying GS, Huang J, Levy NE, Maguire MG; Collaborator, **Dugel, P**. Am J Ophthalmology. 2014

***VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).*** Randomized controlled trial

Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF, Collaborator, **Dugel, P**. JAMA Ophthalmology. 2014

***Fungal endophthalmitis associated with compounded products.*** Mikosz CA, Smith RM, Kim M, Tyson C, Lee EH, Adams E, Straif-Bourgeois S, Sowadsky R, Arroyo S, Grant-Greene Y, Duran J, Vasquez Y, Robinson BF, Harris JR, Lockhart SR, Török TJ, Mascola L, Park BJ, Collaborator, **Dugel, P**. Emerg Infect Dis. 2014

***Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab.***

Channa R, Sophie R, Khwaja AA, Do DV, Hafiz G, Nguyen QD, Campochiaro PA, Collaborator, **Dugel, P**.; READ-2 Study Group. Eye (Lond). 2014 Mar;28(3):269-78. doi: 10.1038/eye.2013.245. Epub 2013 Nov 22 PMID: 24263379.

***Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results****.* Petrarca R, **Dugel PU**, Bennett M, Barak A, Weinberger D, Nau J, Jackson TL. Retina. 2014 May;34 (5):874-9. doi: 10.1097/IAE.0000000000000026.

***Individualized, spectral domain-optical coherence tomography-guided facedown posturing after macular hole surgery: minimizing treatment burden and maximizing outcome.***  Yamashita T, Sakamoto T, Yamashita T, Sonoda S, Yamakiri K, Otsuka H, Hisatomi T, Imaki H, Ishibashi T, **Dugel PU**. Retina. 2014 Jul;34(7):1367-75. Doi:10.1097/IAE.0000000000000087. PMID: 24955569 [PubMed - in process]

***Machines and Cutters: Constellation®.*** Witmer MT, **Dugel PU**. Dev Opthalmol. 2014;54:1-7. Doi: 10.1159000360442. Epub 2014 Aug 26

**2013**

***The Ins & outs of joining an ambulatory surgical center*. Dugel PU**. Ophthalmic Surg Lasers Imaging Retina. 2013 Jan-Feb; 44(1):6-8. doi: 10.3928/23258160-20130103-02. PMID: 23410806 [PubMed - indexed for MEDLINE]

***Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.*** Jackson TL, **Dugel PU**, Bebchuk JD, Smith KR, Petrarca R, Slakter JS, Jaffe GJ, Nau JA; CABERNET Study Group. Ophthalmology. 2013 Aug;120(8):1597-603. doi: 10.1016/j.ophtha.2013.01.074. Epub 2013 Mar 13. PMID: 23490325 [PubMed - indexed for MEDLINE]

***Diagnostic and therapeutic challenges.*** Turaka K, Gordon AJ, Patel S, Bryan JS, Kwong HM Jr, **Dugel PU,** Arogyasami RM. Retina. 2013 Mar;33(3):661-5. doi: 10.1097/IAE.0b013e3182757374. PMID: 23386115 [PubMed - indexed for MEDLINE]

***Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE)*** Petrarca R, **Dugel PU,** Nau J, Slakter JS, Jaffe GJ, Jackson TL. [: month 12 optical coherence tomography and fluorescein angiography.](http://www.ncbi.nlm.nih.gov/pubmed/23178157) *Ophthalmology.* 2013 Feb;120(2):328-33. doi: 10.1016/j.ophtha.2012.07.091. Epub 2012 Nov 22.

***Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.*** Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, Hafiz G, Campochiaro PA, Collaborator, **Dugel, P**; READ-2 Study Group. JAMA Ophthalmology. 2013 Feb; 131(2): 139-45. PMID: 23544200 [PubMed - indexed for MEDLINE]

***Business principles essential to survival in today's climate.* Dugel PU.** Ophthalmic Surg Lasers Imaging Retina. 2013 Mar-Apr; 44(2): 117-9. doi: 10.3928/23258160-20130313-03. No abstract available. PMID: 23510036 [PubMed - indexed for MEDLINE]

***Tiny Bubbles***. **Dugel PU**. Retina. 2013 Apr;33 (4):684-5. doi: 10.1097/IAE.0b013e318287da80. PMID: 23528702 [PubMed - indexed for MEDLINE]

***Aflibercept-related sterile inflammation.*** Hahn P, Kim JE, Stinnett S, Chung MM, **Dugel PU**, Flynn HW Jr, Huang SS, Sadda SR, Mahmoud TH; American Society of Retina Specialists Therapeutic Surveillance Committee. Ophthalmology. 2013 May; 120(5): 1100-101.e1-5. doi: 10.1016/j.ophtha.2012.11.018. PMID: 23642742 [PubMed - indexed for MEDLINE]

***Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis.***

Stalmans P, Duker JS, Kaiser PK, Heier JS, **Dugel PU,** Gandorfer A, Sebag J, Haller JA. Retina. 2013 Nov-Dec;33(10):2003-11. doi: 10.1097/IAE.0b013e3182993ef8. Review. PMID: 23881226 [PubMed - indexed for MEDLINE]

***Employing information systems to shore up retina practices for the next phase of health care.* Dugel PU,** Gupta S. Ophthalmic Surg Lasers Imaging Retina. 2013 Jul-Aug; 44(4): 330-2. doi: 10.3928/23258160-20130715-03. No abstract available. PMID: 23883267

***Electronic health records: Future business applications: Part 1 in a two-part series****.* Wang R, **Dugel PU**. *Ophthalmic Surgical Lasers Imaging Retina.* 2013 Sep 1; 44(5): 439-41. doi: 10.3928/23258160-20130909-03.

***Electronic health records: future clinical applications. Part 2 in a two-part series.***

Wang R, **Dugel PU**. Ophthalmic Surgical Lasers Imaging Retina. 2013 Nov 1; 44(6):528-30. doi: 10.3928/23258160-20131105-02. PMID: 24221460

***Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab.*** Channa R, Sophie R, Khwaja AA, Do DV, Hafiz G, Nguyen QD, Campochiaro PA, Collaborator, **Dugel, P**; The READ-2 Study Group. *Eye* (Lond). 2013 Nov 22. doi: 10.1038/eye.2013.245. [Epub ahead of print]

***Macular Epiretinal Brachytherapy in Treated Age-Related Macular Degeneration (MERITAGE):*** Month 24 Safety and Efficacy Results. Petrarca R, **Dugel PU,** Bennett M, Barak A, Weinberger D, Nau J, Jackson TL*. Retina*. 2013 Oct 28. [Epub ahead of print]

***Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial******(CABERNET).*** **Dugel PU,** Bebchuk JD, Nau J, Reichel E, Singer M, Barak A, Binder S, Jackson TL; CABERNET Study Group. Ophthalmology. 2013 Feb;120(2):317-27. doi: 10.1016/j.ophtha.2012.07.068. Epub 2012 Nov 20. PMID: 23174399 [PubMed - indexed for MEDLINE]

**2012**

***Epimacular brachytherapy for the treatment of retinal angiomatous proliferation.*** Petrarca R, Nau J, **Dugel PU**, Jackson TL. Retin Cases Brief Rep. 2012 Fall; 6(4): 353-7. doi: 10.1097/ICB.0b013e31823c12a3. PMID: 25389929 [PubMed]

***Tissue attraction associated with 20-gauge, 23-gauge, and enhanced 25-gauge dual-pneumatic vitrectomy probes.* Dugel PU**, Zhou J Abulon DJ, Buboltz DC. Retina. 2012 Oct; 32(9): 1761-6. PMID: 22466488 [PubMed - indexed for MEDLINE]

***Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.*** **Dugel PU**, Petrarca R, Bennett M, Barak A, Weinberger D, Nau J, Jackson TL.

Ophthalmology. 2012 Jul;119(7):1425-31. doi: 10.1016/j.ophtha.2012.01.014. Epub 2012 Mar 30. PMID: 22465819 [PubMed - indexed for MEDLINE]

***Proportional reflux hydrodissection.* Dugel PU.** Retina. 2012 Mar;32 (3):629-30. doi: 10.1097/IAE.0B013E31824453C7. PMID: 22374158 [PubMed - indexed for MEDLINE]

***A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema.*** **Dugel PU**, Blumenkranz MS, Haller JA, Williams GA, Solley WA, Kleinman DM, Naor J.

Ophthalmology. 2012 Jan; 119(1): 124-31. doi: 10.1016/j.ophtha.2011.07.034. Epub 2011 Nov 23. PMID: 22115710 [PubMed - indexed for MEDLINE]

***Advances in the Treatment of Wet Age-Related Macular Degeneration.*** Kaiser PK, **Dugel PU,** Ho AC, Martin DF, Puliafito CA. *Retina*. CME supplement

***Epimacular Brachytherapy for the Treatment of Retinal Angiomatous Proliferation***. Petrarca R, Nau J, **Dugel PU,** Jackson T. *Ophthalmic Communications Society, Inc.* 2012

***Macular Epiretinal Brachytherapy in Treated Age-Related Macular Degeneration, Meritage Study: Twelve-Month Safety and Efficacy Results.*** **Dugel PU**, Petrarca R, Bennet M, Barak A, Weinberger D, Nau J, Jackson T. *Ophthalmology.* 2012

***Tissue attraction associated with 20-gauge, 23-gauge, and enhanced 25-gauge dual-pneumatic vitrectomy probes.* Dugel**, PU, Zhou, J, Abulon DJ, Buboltz DC. *Retina*. 2012 Oct; 32(9): 1761-6.

**2011**

***Endophthalmitis in microincision vitrectomy: outcomes of gas-filled eyes.*** Chiang A, Kaiser RS, Avery RL, **Dugel PU,** Eliott D, Shah SP, Heier J, Duker J, Hu AY, Schwartz SD, Scott IU, Pollack JS, Faia LJ, Williams GA. Retina. 2011 Sep;31(8):1513-7. doi: 10.1097/IAE.0b013e3182209290. PMID: 21878799 [PubMed - indexed for MEDLINE]

***Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2****.* Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, Wolka AM, Shahri N, Milton RC, Collaborator, **Dugel, P**; PKC-DRS and PKC-DRS2 Study Groups. Retina. 2011 Nov; 31(10): 2084-94. doi: 10.1097/IAE.0b013e3182111669.PMID: 21862954

***Development of an activity-based costing model to evaluate physician office practice profitability.* Dugel PU,** Tong KB. Ophthalmology. 2011 Jan; 118(1):203-208.e1-3. doi: 10.1016/j.ophtha.2010.04.035. Epub 2010 Aug 14. PMID: 20709400 [PubMed - indexed for MEDLINE]

***Development of an Activity-Based Costing Model to Evaluate Physician Office Practice Profitability.*** **Dugel PU,** Tong KB. *Ophthalmology* 2011 Jan;118(1):203-8.e1-3. Epub 2010 Aug 14.

***Evaluation of economic efficiencies in clinical retina practice: activity-based cost analysis and modeling to determine impacts of changes in patient management.*** Murray TG, Tornambe P, **Dugel P,** Tong KB. *Clin Ophthalmology* 2011 5: 913-25. Epub 2011 Jul 12.

***Endophthalmitis in Microincision Vitrectomy: Outcomes of Gas-Filled Eyes.*** Chiang A, Kaiser RS, Avery RL, **Dugel PU,** Eliott D, Shah SP, Heier J, Duker J, Hu AY, Schwartz SD, Scott IU, Pollack JS, Faia LJ, Williams GA. *Retina* 2011 Sep;31(8):1513 – 7.

**2010**

***The Microsurgical Safety Task Force: Evolving Guidelines for Minimizing the Risk of Endophthalmitis Associated With Microincisional Vitrectomy Surgery.*** Kaiser RS, Prenner J, Scott IU, Brucker AJ, Flynn, Jr. HW, Williams GA, Ho AC, Regillo CD, Capone A, Avery R , Eliott D, **Dugel PU,** Pollack J. *Retina* 2010 Apr;30(4):692 – 9

***Two-Year Outcomes of the Ranibizumab for Edema of the Macula in Diabetes (READ-2) Study.*** Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, Boyer D, Heier JS, Abraham P, Thach AB, Lit ES, Foster BS, Kruger E, **Dugel P,** Chang T, Das A, Ciulla TA, Pollack JS, Lim JI, Eliot D, Campochiaro PA, READ-2 Study Group. *Ophthalmology* 2010 Nov;117(11): 2146-51

**2009**

***Evaluation of the Safety and Performance of an Applicator for a Novel Intravitreal Dexamethasone Drug Delivery System for the Treatment of Macular Edema.*** Haller JA, **Dugel PU,** Weinberg DV, Chou C, Whitcup SM: *Retina* 2009 Jan; 29(1): 46-51

***Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.***

Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, Abraham P, Campochiaro PA, Collaborator, **Dugel P**.; READ-2 Study Group. Ophthalmology. 2009 Nov;116(11):2175-81.e1. doi: 10.1016/j.ophtha.2009.04.023. Epub 2009 Aug 22. PMID: 19700194 [PubMed - indexed for MEDLINE]

**2008**

***Short-term outcomes of 23-gauge pars plana vitrectomy.*** Gupta OP, Ho AC, Kaiser PK, Regillo CD, Chen S, Dyer DS, **Dugel PU**, Gupta S, Pollack JS. Am J Ophthalmol. 2008 Aug;146(2):193-197. doi: 10.1016/j.ajo.2008.04.010. Epub 2008 Jun 10. PMID: 18547538 [PubMed - indexed for MEDLINE]

**2006**

***Ranibizumab treatment of patients with ocular diseases.* Dugel PU**. Int Ophthalmol Clin. 2006 Fall; 46(4):131-40. Review. No abstract available. PMID: 17060799 [PubMed - indexed for MEDLINE]

***Diagnostic and therapeutic challenges.*** Zumbro DS, Sanders JB, Boldt HC, Novack RL, **Dugel PU,** Klein ML. Retina. 2006 May-Jun;26(5):571-7. No abstract available. PMID: 16770265 [PubMed - indexed for MEDLINE]

***Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage: proceedings of an expert panel roundtable discussion.*** Nguyen QD, Callanan D, **Dugel PU,** Godfrey DG, Goldstein DA, Wilensky JT. *Retina* 2006 Oct;Suppl 1-16

**2005**

***Diagnostic and therapeutic challenges. Progressive bilateral visual loss over the last seven years.***

Drenser KA, Williams GA, Fu AD, Egan C, Hykin PG, **Dugel PU**, Rao PK. Retina. 2005 Sep; 25(6): 778-83. PMID: 16141868 [PubMed - indexed for MEDLINE]

**2003**

***Large-spot size transpupillary thermotherapy for the treatment of occult choroidal neovascularization associated with age-related macular degeneration.*** Thach AB, Sipperley JO, **Dugel PU,** Sneed SR, Park DW, Cornelius J. Arch Ophthalmol. 2003 Jun;121(6):817-20. PMID: 12796252 [PubMed - indexed for MEDLINE]

***Macular pucker removal with and without internal limiting membrane peeling: pilot study.***

Park DW, **Dugel PU,** Garda J, Sipperley JO, Thach A, Sneed SR, Blaisdell J. Ophthalmology. 2003 Jan;110(1):62-4.

PMID: 12511347 [PubMed - indexed for MEDLINE]

**2002**

***Progressive subretinal fibrosis and blindness associated with multifocal granulomatous chorioretinitis: A variant of sympathetic ophthalmia.*** Wang RC, Zamir E, **Dugel PU,** Sipperley JO, Thirkill CE, Shabatian B, Rao NA.

Ophthalmology. 2002 Aug; 109(8): 1527-31. PMID: 12153806 [PubMed - indexed for MEDLINE]

**2001**

***Massive suprachoroidal hemorrhage during pars plana vitrectomy associated with Valsalva maneuver.*** Pollack AL, McDonald HR, Ai E, Johnson RN, **Dugel PU,** Folk J, Grand MG, Lambert HM, Schwartz S, Miller RD. Ophthalmology 2001 Sep; 132(3): 383-7

***Juvenile xanthogranuloma masquerading as pediatric chronic uveitis; a clinicopathologic study.*** Zamir E, Wang RC, Krishnakkumar S, Aiello Leverant A, **Dugel PU**, Rao NA. Surv Ophthalomology2001 Sep-Oct;46(2):164-71

**2000**

***Outcome of sulcus fixation of dislocated posterior chamber intraocular lenses using temporary externalization of the haptics.*** Thach AB, **Dugel PU**, Sipperley JO, Sneed SR, Hollifield RD, Park DW, Jacobsen J, Howard RS, Ward TP. Ophthalmology 2000 Mar; 107(3): 480-4

**1999**

***Ocular injuries from paintball pellets.*** Thach AB, Ward TP, Hollifield RD, **Dugel PU,** Sipperley JO, Marx JL, Abrams DA, Wroblewski KJ, Sonkin PL, Birdsong RH, Dunlap WA. Ophthalmology 1999 Mar; 106(3): 533-7

***Macular hole surgery with internal–limiting membrane peeling and intravitreous air.*** Park DW, Sipperley JO, Sneed SR, **Dugel PU**, Jacobsen J. Ophthalmology 1999 Jul; 106(7): 1392-7

***Pars plana vitrectomy without scleral buckle for pseudophakic retinal detachments.*** Campo RV, Sipperley JO, Sneed SR, Park DW, **Dugel PU**, Jacobsen J, Flindall RJ. Ophthalmology 1999 Sep; 106(9): 1811-5

**1997**

***Presumed multifocal cryptococcal choroidopathy prior to specific systemic manifestation.*** Rostamian K, **Dugel PU**, Kolahdouz-Isfahani A, Thach AB, Smith RE, Rao NA*.* Int Ophthalmology 1997; 21(2): 75 – 8

***Annular peripheral choroidal detachment simulating aqueous misdirection after glaucoma surgery.*** **Dugel PU,** Heuer DR, Thach AB, Baerveldt G, Lee PP, Lloyd MA, Minckler DS, Green RL. Ophthalmology 1997 Mar; 104(3): 439-444

***A comparison of retrobulbar versus sub-tenon’s corticosteroid therapy for cystoid macular edema refractory to topical medications.*** Thach AB, **Dugel PU**, Flindall RJ, Sipperley JO, Sneed SR: Ophthalmology 1997 Dec; 104(12): 2003-8

**1996**

***Tumor necrosis factor-alpha (TNF-alpha)-induced optic neuropathy in rabbits.*** Madigan MC, Saun AA, Rao NS, **Dugel PU,** Tenhula WN, Gill PS. Neurol *Res.* 1996 Apr; 18 (2): 176-84

**1995**

***Clinicopathologic study of retinal and choroidal biopsies in intraocular inflammation.*** Rutzen AR, Ortega-Larrocea G, **Dugel PU**, Chong LP, Lopez, PF, Smith RE, Rao NA. Am J Ophthalmology 1995 May;119(5):597-661

**1994**

***Echographic findings in infectious endophthalmitis*.** Dacey MP, Valencia M, Lee MD, **Dugel PU**, Ober RR, Green RL, Lopez PF. Invest Ophthalmology Vis Sci 35: 1285

***Rhegmatogenous retinal detachments after Molteno glaucoma implant surgery*.** Waterhouse JJ, Lloyd ME, **Dugel PU**, Heuer, DR, Baerveldt G, Minckler DS, Liggett PE. Ophthalmology 1994 Apr; 101(4): 665-71

***Macular Hole Syndromes-Echographic findings with clinical correlation*.** **Dugel PU**, Smiddy WE, Byrne SF, Hugehs JR, Gass JDM. Ophthalmology1994 May;101(5): 815-21

***Retinal and choroidal biopsy in intraocular inflammation: a clinicopathologic study*.** Rutzen AR, Ortetga-Larrocea G, **Dugel PU,** Chong LP, Rao NA. Trans Am Ophthalmology Soc 92: 431-458

***Human T-cell lymphotrophic virus type 1- associated retinal lymphoma. A Clinicopathologic Report.*** Kumar SR, Gill PS, Wagner DG, **Dugel PU,** Moudgil T, Rao NA. Arch Ophthalmology 1994 Jul;112(7):954-9

**1993**

***Goals of the academy’s committee on recredentialing*.** **Dugel PU**. Argus 26: 32

***Opportunistic intraocular infections in AIDS*.** Morinelli EN, **Dugel PU**, Rao NA. *Trans Am* Ophthalmol Soc 1992; 90:97-108

***Nontraumatic juvenile inferiotemporal dialysis.*** Yoon YH, Ober RR, Frambach DA, Wagner DG, **Dugel PU**, Stout JT, Chu TG. Invest. Ophthalmol Vis Sci 34: 954

***Rhegmatogenous retinal detachment after Molteno glaucoma implant surgery*.** Waterhouse WJ, Lloyd MA, **Dugel PU**, Heuer DK, Baerveldt G, Minckler DS, and Liggett PE. Invest. Ophthalmol Vis Sci 34: 1211

***Effect of maximal physical exertion on intraocular pressure.*** Wagner DG, **Dugel PU**. Invest. Ophthalmology Vis Sci 34: 735`

***Sensory visual dysfunction in AIDS patients*.** Benjamin MJ, **Dugel PU**, Silverman SE, Liu P, Sadun, AA, Rao NA, Frambach DA. Invest. Ophthalmol Vis Sci 34: 1416

***Infectious multifocal choroiditis in patients with acquired immunodeficiency syndrome.*** Morinelli EN, **Dugel PU**, Riffenburgh R, Rao NA. Ophthalmology 1993 Jul; 100(7):1014-21

***Macular and extramacular microvascular abnormalities in AIDS patients.*** **Dugel PU**, Benjamin MJ, Liu P, Silverman SE, Sadun AA, Rao NA, Frambach DA. Invest. Ophthalmology Vis Sci 34:1057

***Intermediate uveitis (pars planitis).*** **Dugel PU**, Smith RE. Ophthalmology Clinics of North Am 6: 29

***Ocular infections in the acquired immunodeficiency syndrome*.** **Dugel PU**, Rao NA. International Ophthalmol Clinics 33:103

**1992**

***Ocular manifestations of acquired immunodeficiency syndrome.*** Frangieh GT, **Dugel PU,** and Rao NA. Current Opinion in Ophthalmology 3: 228

***Postoperative bacterial contamination of the aqueous humor*.** Ariyasu RG, **Dugel PU**, Nakamura T, Trousdale M, and Smith RE. Invest. Ophthalmol Vis Sci 33: 1421

***Time and dose dependent axonal losses in rabbit optic nerves exposed to tumor necrosis factor (TNF)*** Rao NS, Madigan MC, Tenula WN, **Dugel PU**, Sadun AA, Gill PS. Invest Ophthalmol Vis Sci 33: 817

***Opportunistic intraocular infection in AIDS.*** Morinelli, EN, **Dugel PU,** Walker J, Riffenburg R, Klatt EC, Rao NA. *Invest*. Ophthalmology Vis Sci 33: 750

***Mycobacterium fortuitum keratitis: clinicopathologic correlates and corticosteroid effects in an animal model.*** Paschal, JF, Holland GN, Sison RF, Berlin OGW, Bruckner, DA, **Dugel PU,** Foos RY: Cornea 1992 Nov; 11(6): 493-9

***Retinal microvascular abnormalities in the acquired immunodeficiency syndrome*.** Rao K, **Dugel PU**, Morinelli EN, Rao NA. Invest. Ophthalmology Vis Sci 33: 742

***Treatment of ocular adnexal Kaposi’s sarcoma in acquired immune deficiency syndrome.*** **Dugel PU**, Gill PS, Frangieh GT, Rao NA. Ophthalmology 1992 Jul; 99(7):1127-32

***Pars plana vitrectomy for intraocular inflammation-related cystoid macular edema unresponsive to corticosteroids.*** **Dugel PU**, Rao NA, Ozler, S, Liggett PE, and Smith RE. Ophthalmology1992 Oct; 99(10): 1535-41

**1991**

***Tumor necrosis factor in AIDS associated optic neuropathy****.* **Dugel PU,** Gill PS, Tenhula WN, Sadun, AA, and Rao, NA. Inves. Ophthalmology Vis Sci 32: 765

***Repair of retinal detachment caused by cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.*** **Dugel PU,** Liggett PE, Lee MD, Ziogas A, Forster DJ, Smith RE, and Rao, NA. Am J Ophthalmology 1991 Sep 15; 112(3): 235-42

**1990**

***Pneumocystis carinii choroiditis*.** Chong LP, **Dugel PU**, Forster DJ, Frangieh GT, and Rao NA. Invest Ophthalmology Vis Sci 31: 365

***Growth factors and receptors in the pathogenesis of ocular adnexal Kaposi’s sarcoma.*** **Dugel PU**, Frangieh GT, Gill PS, and Rao NA. Invest Ophthalmol Vis Sci 3: 369

***Particles resembling retrovirus and conjunctival Kaposi’s sarcoma***. **Dugel PU**, Gill PS, Frangieh GT, Rasheed S, and Rao NA. Am J Ophthalmology 1990 Jul 15;110(1):86-7

***Ocular adnexal Kaposi’s sarcoma in acquired immunodeficiency syndrome.*** **Dugel PU,** Gill PS, Frangieh GT, and Rao NA. Am J Ophthalmology 1990 Nov 15; 110(5): 500-3

***Pneumocystis carinii choroiditis after long-term aerosolized pentamidine therapy.*** **Dugel PU**, Rao NA, Forster, DJ, Chong LP, Frangieh GT, and Sattler F. Am J Ophthalmology 1990 Aug 15; 110(2): 113-7

***Rapidly progressive outer retinal necrosis in the acquired immunodeficiency syndrome.*** Forster DJ, **Dugel PU,** Frangieh GT, Liggett PE, and Rao NA. Am J Ophthalmology 1990 Oct 15; 110(4): 341-8

**1989**

***Intravitreal steroid injection in rabbits.*** Zimmerman PL, Beniz J, **Dugel PU**, and Rao NA. Invest Ophthalmology Vis Sci 30: 1814

***Intravitreal prostaglandin E2 and leukotriene B4 following extracapsular and intracapsular cataract extraction in rabbits.*** **Dugel PU**, Zimmerman PL, Biswas J, Rao NA, and Smith RE. Invest Ophthalomology Vis Sci 30: 1214

**1988**

***Mycobacterium fortuitum keratitis*.** **Dugel PU,** Holland GN, Brown HH, Petit TH, Hofbauer, JD, Simons KB, Ulman H, Bath PE, and Foos RY. Am J Ophthalmology 1988 Jun 15; 105(6): 661-9

**Non- Peer Reviewed Journals**

**2018**

***At 96 Weeks Brolucizumab Outdoes Aflibercept in Reducing Retinal Fluid.*** MD Magazine, **Pravin U. Dugel, MD**, October 28, 2018

***Brolucizumab in the Treatment of Neovascular Age-related Macular Degeneration.*** Touch Ophthalmology (Touch Medical Media), **Pravin U. Dugel, MD**, October 15, 2018

***Brolucizumab: Next Generation of anti-VEGF therapy?*** Modern Retina, **Pravin U. Dugel, MD,** July 22, 2018

***A Smaller, Faster Anti-VEGF Therapy.*** Retina Specialists, **Pravin U. Dugel**, MD, July 3, 2018

***Treatment of DME poses complex choices, strives to overcome limitations.*** Ocular Surgery News, ***Pravin U. Dugel,* MD**, June 25, 2018

***Brolucizumab treatment frequency predicted by first dosing interval,*** Ocular Surgery News, **Pravin U. Dugel, MD,** April 30, 2018

***Ranibizumab Poses No Additional Risk of SAEs During Advanced Age***, MD Magazine, **Pravin U. Dugel, MD,** April 20th, 2018

***Pipeline Update What’s Expected to Emerge in 2018***. Retina Specialist, **Pravin U. Dugel, MD**, March 30th, 2018

***Innovation in Retina Surgery: Technological Innovation is Crucial to the Continued Improvement of Vitreoretinal Surgery***. EUROTIMES, **Pravin U. Dugel, MD**, March 1, 2018

***These Novel Strategies May Change DME Treatment Paradigm.*** Modern Retina, Ophthalmology Times, **Dr. Pravin U. Dugel**, February 19, 2018

**2017**

***Transition from optical to digital opens opportunities in the operation room***. Ocular Surgery News, **Pravin U. Dugel, MD**, November 25, 2017

***Novartis' eye drug clearly works but edging out Eylea won't be easy***. BioPharmaDIVE, **Pravin U. Dugel, MD,** November 13th, 2017

***Novartis' VEGF inhibitor demonstrates clinically relevant anatomic, visual gains***. Ocular Surgery News, **Pravin U. Dugel, MD**, November 11, 2017

***Retinal surgeon expands practice while serving Native American communities and third-world countries.*** Phoenix Business Journal, Healthcare, Entrepreneur, **Pravin U. Dugel, MD**, September 18, 2017

***Progress in Diabetic Retinopathy in the Spotlight at ASRS***, Medscape, Conference News, ASRS 2017 Annual Meeting, **Pravin U. Dugel, MD**, August 8, 2017

***New options under study, but for now anti-VEGF monotherapy remains gold standard for wet AMD.*** Ocular Surgery News, U.S. Edition, **Pravin U. Dugel, MD,** February 25, 2017

**2016**

***Can Long-Term Response to Anti-VEGF Therapy Be Predicted After Three Injections in Patients With DME?***

***A post hoc analysis of the ranibizumab arms from Protocol I points to “yes.”*** Retina Today, **Pravin U. Dugel,**

March 2016

***OASIS trial: Ocriplasmin improves VMA resolution over long term* -** August 10, 2016; Ocriplasmin improved resolution of symptomatic vitreomacular adhesion, according to 2-year results of the OASIS trial. **Dugel PU**, et al. Ophthalmology. 2016;doi: 10.1016/j.ophtha.2016.06.043

***8 Questions with OSLIR***, **Pravin U. Dugel, MD,** Ophthalmic Surgery, Lasers and Imaging Retina, May 2016 - Volume 47 · Issue 5: 498-500

***Imaging of Melanin Disruption in Age-Related Macular Degeneration Using Multispectral Imaging***, **Pravin U. Dugel, MD;** Cheryl N. Zimmer, OD, Ophthalmic Surgery, Lasers and Imaging Retina, February 2016 - Volume 47 · Issue 2: 134-141

***Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin***, Timothy L. Jackson, PhD; Carl D. Regillo, MD; Aniz Girach, MD; **Pravin U. Dugel, MD**, Ophthalmic Surgery, Lasers and Imaging Retina, August 2016 - Volume 47 · Issue 8: 716-723

**2015**

***Improving Outcomes for Patients With Diabetic Macular Edema***, Carmen A. Puliafito, MD, MBA; **Pravin U. Dugel, MD**; Scott W. Cousins, MD; Kirk H. Packo, MD; Alexander M. Eaton, MD; Richard K. Parrish II, MD; Szilárd Kiss, MD; Elias Reichel, MD, Ophthalmic Surgery, Lasers and Imaging Retina, November/December Supplement 2015 - Volume 46 · Issue 10: S5-S15

***Diabetic Macular Edema Diagnosis and Treatment in the Real World: An Analysis of Medicare Claims Data (2008 to 2010)***, **Pravin U. Dugel, MD**; Andrew Layton, BA; Rohit Varma, MD, MPH, Ophthalmic Surgery, Lasers and Imaging Retina, March 2016 - Volume 47 · Issue 3: 258-267

**2014**

***Regulation of Quality in the ASC: The Good, the Bad, and the Ugly: Part 2 in a Two-Part Series,*** Michael A. Romansky, JD; **Pravin U. Dugel, MD**, Ophthalmic Surgery, Lasers and Imaging Retina, March/April 2014 - Volume 45 · Issue 2: 101-104

***The Regulatory Climate for Ambulatory Surgery Centers: Opportunities Abound for the Retinal Specialist,*** Michael A. Romansky, JD; **Pravin U. Dugel, MD**, Ophthalmic Surgery, Lasers and Imaging Retina, January/February 2014 - Volume 45 · Issue 1: 14-16

***New vitrectomy technologies advance precision, efficiency during surgery*** – **Dugel PU**, Opthalmology Times, November 2014

***Focusing on Success in Retinal Surgery, 4 keys to capitalizing on the specialty's rapidly changing nature****,* Outpatient Surgery Magazine, 11/14, **Dugel PU**

***Proportional Reflux Hydrodissection, Retina***- The Journal of Retinal and Vitreous Diseases, **Dugel PU**, December 2014

***Considering the Long-Term Effects of Anti-VEGF Treatment***, Retina Times, **Dugel PU,** Fall 2014

**2013**

***Business principles essential to survival in today’s climate***, **Pravin U. Dugel, MD**, Ophthalmic Surgery, Lasers and Imaging Retina, March/April 2013 - Volume 44 · Issue 2: 117-119

***The Ins and Outs of Joining an Ambulatory Surgical Center,* Pravin U. Dugel, MD,** Ophthalmic Surgery, Lasers and Imaging Retina, January/February 2013 - Volume 44 · Issue 1: 6-8

***A Paradigm Shift for DME*,** Ophthalmology Times, **Dugel PU,** March 2013

***Moderator, Special Report: Part 1 of 2: Per-Patient Compounding Prescription Regulations: The End of the Road for Avastin?*** *Retina Times*, **Dugel PU,** 2013 Spring; 31(48): 24-29

***Moderator, Special Report: Part 2 of 2: The Future of Avastin: Balancing Safety and Cost-Effectiveness****.* Retina Times, **Dugel PU**, 2013 Summer; 31(49): 18-20

***Editor, Research and Development: Training India’s Retina Surgeons in Sutureless Microincisional Vitrectomy*.** Retina Times, **Dugel PU**, 2013 Meeting: 31(50): 28-30; 57

***The Susrut Sutureless Microincisional Vitrectomy Training Program—A US Faculty Member’s Perspective.*** Retina Times, **Dugel PU**, 2013 Meeting: 31(50): 29

***Visual Cycle Modulation: A Novel Therapeutic Approach for Treatment of GA in Dry AMD****.* Mata NL, Kubota R, **Dugel PU**, Retinal Physician May 2013

***Pharmacodynamics of Visual Cycle Modulation in the Treatment of GA.*** Mata NL, Kubota R, Schneider S, Kissner J, Birch DG, **Dugel PU**, Retinal Physician Sept 2013

**2012**

***Radiation Treatments for Neovascular AMD***. **Dugel PU**, Retina Today 2012 Mar; 7(2): 56-8

***A New Focus on the Vitreous and Its Role in Retinal Function*.** **Dugel PU**, Retina Today 2012 Apr; 7(3): 50-3

***The Evolution of Understanding Vitreomacular Adhesion*.** **Dugel PU**, Retina Today May 2012 Supplement

***Round Table Discussion (CME activity): Advances in the Treatment of Wet Age-Related Macular Degeneration.* Dugel, PU,** Supplement to Retina, May 15, 2012

***The CATT 2-Year Results: What do they mean?*** **Dugel, PU**, Retina Vitreous*.* May 16, 2012

***Anti-PDGF, anti-VEGF combination may be game changer in wet AMD treatment.* Dugel, PU**. Retina Vitreous, June 14, 2012

***ASRS Symposium, Part 1: Applying AMD Trial results to Clinical Practice.*** Panel Moderator, Retina Times 2012 Fall; 30(46): 26-31

***Visual Cycle Modulators*.** **Dugel, PU**. Retina Vitreous*.* September 12, 2012

***Eyelea a welcome option for treatment of macular edema due to CRVO*.** **Dugel, PU.** Retina Vitreous. September 26, 2012

***Another Option for Patients with Vitreomacular Adhesion.*** **Dugel, PU**. Retinal Physician*.* October 2012

***Anti-PDGF Drug Targets Heart of Angiogenesis: Novel Combination AMD Therapy Yields Startlingly Good Outcomes, A study Investigator Reports*.** **Dugel PU.** Retinal PhysicianOctober 1,2012.Jul; 119(7):1425-31. Epub 2012 Mar 30

***Applying DME Trial Results to Clinical Practice.*** Panel Moderator, ASRS Symposium, Part 2: Retina Times 2012 Winter; 30(47):34-37

**2011**

***The Second Annual OIS Forum: 150 Million-Aging Eyes Spell Opportunity.*** **Dugel P**, Cunningham E. Retinal Physician 2011 Jan; 8(1): 68-9

***Bacterial Contamination and Incidence Rates of Infectious Endophthalmitis Following Transconjunctival Sutureless Vitrectomy: How to Minimize the Risk*.** Section Editor, Research and Development: Retina Times 2011 Spring; 29(38):26-8

***The RUC: What Is It and How Does It Affect Your Practice?*** **Dugel PU,** McNett CL, Topping TM. Retina Times 2011 Summer; 29(39): 12-14 Section Editor, Research and Development: Treatment of Symptomatic Vitreomacular Adhesions: Promise and Progress. *Retina Times* 2011 Summer; 29(39): 34-7

***Molecular Research in Uveal Melanoma: Ushering in a New Standard of Care. Section Editor, Research and Development***: Retina Times Summer 2011; 29(40): 26-37

***Controversies in Care: The CATT’s Whiskers*.** Colucciello M, Adamis AP, Barron HV, **Dugel PU**. Retinal Physician 2011 Jul;8(6): 14-19

***Innovation in Retina. Samir Patel: A Pioneer in Anti-VEGF*.** Section Co-Editor: Retinal Physician 2011 Jul ;8(6)

***Symptomatic vitreomacular adhesion.*** Brown DM, **Dugel PU**, Humayun MS, Kaiser PK, Trese MT. Retina Today 2011 Jul; 6(5): S1-16

***Other Considerations with the Dexamethasone Intravitreal Implant.*** **Dugel PU**. Retina Today Insert 2011 July

***Highlights of the CATT Study Expert Panel Discussion*.** Panel Moderator, ASRS Research and Therapeutics Symposium: Retina Times 2011 Fall; 29(41): 14-7

***A New ILM-Staining Composition: From Development to Clinical Application. Part 1: Biocompatibility of Brilliant Blue G (BBG) as a Preclinical Investigation for Vitrectomy. Section Editor, Research and Development****:* Retina Times 2011 Fall; 29(41): 27-31

***New Parameters in Vitreoretinal Surgery.*** **Dugel PU,** Buboltz D. Retina Today 2011 Oct; 6(7):83-8

***New Techniques for Tissue Separation.*** **Dugel PU.** Retinal Physician 2011 October

***The Public’s Distorted Views on CATT Data.* Dugel PU**. Guest Editorial: Retinal Physician 2011 October

***Steroids for the Treatment of Diabetic Macular Edema.*** Round-Table Discussion (CME activity): Supplement to Retina Today November/December 2011.

***From Refractive to Retina.*** Editor: Innovation in Retina. J Andy Corley: Retinal Physician 2011 November

***Treatment Burden and New Therapies.*** Panel Moderator, ASRS Symposium, Part 2: Retina Times 2011 Winter; 29(42): 19-22

***Vitreoretinal Dissection Techniques for Diabetic Tractional Retinal Detachment.*** **Dugel PU**. Retina Today Insert 2011 December

**2010**

***Managing the Future of Retina Care.*** **Dugel PU**. Ophthalmology Management2010 May*:* 15 – 17

***Better Instrument Design, Increased Indications Boost Popularity of MIVS.*** **Dugel PU.** Ocular Surgeon News, U. S. Edition, September 25, 2010.

***What Does the SCORE Study Mean for My Patients and Me?*** Moshfeghi AA, **Dugel PU.** Retina Times 2010 Spring; 28(33): 26-29.

***Voclosporin: A New Potential Therapeutic Agent for Noninfectious Uveitis***. Sepah YJ, Hatef E, Nguyen QD, **Dugel PU**. Retina Times 2010 Summer; 28(34): 39-40.

***Sirolimus: A New Potential Therapeutic Agent for Noninfectious Uveitis*.** Sepah YJ, Ibrahim M, Channa R, Hatef E, Nguyen QD, **Dugel PU**. Retina Times Special Edition 28(35): 29-31

***A Brave New World: The Retina Subspecialty is in the Vanguard of Changes to Clinical Practice and Reimbursement.*****Dugel PU**, Palanki R, Tong KB. Retinal Physician 2010 Jul;7 (7):12-13

***A New Paradigm in the Treatment of Diabetic Macular Edema in the Anti-VEGF Era: An assessment of risks, and benefits, as well as costs*.** Schimel AM, Shirodkar AR, Flynn HW, **Dugel PU**,Retina Times 2010 Fall; 28(36):23-24

***Retinal Vein Occlusions: Transferring Studies into Clinical Practice.*** Singer M, **Dugel PU,** Retina Times 2010 Fall; 28(36): 38-41

***A “Tipping Point” for Retina R&D: Implications and Expectations*.** **Dugel PU**, Cunningham E. Retinal Physician 2010 Sep; 7(7): 12-13

***Efficiency in Vitreoretinal Surgery = Safety: Fluidics stability and tissue separation are key components.*** **Dugel PU**, Retina TodayInsert 2010 Sep

***Choosing a Gauge for Vitrectomy: Why Go Smaller?*** **Dugel P**. Retinal Physician 2010 Oct; 7(8):S4-5

***Reducing the Treatment Burden for AMD: Combination therapy with anti-VEGF plus epimacular brachytherapy holds promise.*** **Dugel PU.** Retina Today2010 Oct: 66-70

***Panel Discussion: The Complexities of Intraocular Injections: An Expert Panel Discussion.*** **Dugel PU**, Huang S. Retina Times 2010 Winter; 28(37):9-15

***Continuous Evolution in Microincision Vitrectomy Surgery: A 27-Gauge Vitrectomy System.*** Oshima Y, **Dugel PU**. Retina Times 2010 Winter; 28(37): 33-5

***5 Questions with Pravin Dugel***, MD. Retina Today 2011 December

***Moving Retina to the ASC: Is it Right for You?*** Section Editor: Vander J. Retina Today2010 Nov: 32-33.

**2009**

***Early clinical experience with the CONSTELLATION Vision System*.** **Dugel PU.** Retinal Physician Special Issue: 21-4

***Early Clinical Experience with the CONSTELLATION® Vision System: Safety is always top priority, but increased efficiency is a critical benefit for the ASC.*** **Dugel P**. Retinal Physician Special Issue: 21-24

***Retina in the ASC.*** **Dugel PU**, Romansky MA. Retinal Physician 2009 Mar; 6(2): 22-5

***Surgical Efficiencies in the ASC Setting.*** **Dugel PU**. Retina Today2009 Apr: 53-56.

***Are sutures necessary in minimally invasive surgery?* Dugel PU,** Patel A. Retinal Physician 2009 Apr; 6(3):38-44

***Rethinking Intraocular Pressure Requirements: Panelists Describe the Clinical Impact of IOP Compensation. Panel Discussion.*** Retinal Physician 2009 Apr; 6(3) Suppl:12-13

***Aspiration Flow Control: A “Speed Bump” in Vitrectomy?*** Panel Discussion. Retinal Physician2009 Apr*;* 6(3) Suppl: 10-11

***Dawn of a New Era?*** Panel Discussion. Retinal Physician 2009 Apr; 6(3) Suppl: 3-7

***Considering the Utility of Multiple Light Sources and RFID.*** Panel Discussion. Retinal Physician 2009 Apr; 6(3) Suppl: 14

***Radiobiology of epimacular brachytherapy for the treatment of CNV secondary to AMD*.** **Dugel PU**, Nau J, Palanki R. Retinal Physician 2009 May; 6(4): 17-22

***Efficiency, Adaptability are Keys to Maintaining a Healthy Practice.*** Panel Discussion. Retinal Physician 2009 Jun; 6(5) Suppl: 10-13

***Reimbursement Scenario Evolves with New Practice Patterns.*** Panel Discussion Moderator. Retinal Physician 2009 Jun; 6(5)Suppl: 3-4

***Application of Financial Analysis to Three Retina Practices.*** Panel Discussion. Retinal Physician 2009 Jun; 6(5) Suppl: 5-9

***Role of Radiation in the Treatment of Wet AMD: Facts & Myths.* Dugel PU**, Murray T, Nau J, Palanki R. Retina Times 2009 Summer; 27(29): 15 – 18

***Improving Productivity in an ASC Setting*.** **Dugel P**, Gupta S. Retinal Physician 2009 Sep; 6(7): S1-6

***Sirolimus in the Treatment of Retinal Diseases*.**  **Dugel PU**, Retina Today2009 Oct: 38-41.

***IOL Fixation Techniques, The Case for AGIOL*.** Jamal KN, **Dugel PU**, Retinal Physician 2009 Oct; 6(8):30-3

***Diversification Helps Practice Keep Growing: Investments and other nonmedical business models provide stability.*** **Dugel PU**, Retina Today2009 Dec: 76-8.

**2008**

***Retina ambulatory surgery center myths debunked*.** **Dugel PU,** Romansky MA, Charles S. Retinal Physician 2008 Jan; 5(1): 48-52

***Retina Comes of Age in the ACS Setting. The time has come to integrate retinal procedures and surgical efficiencies.*** **Dugel PU**. Retina Today2008 Mar; 31-32.

***Physician Ownership of ASCs: Issues and Options for Retinal Specialists.*** Romansky MA, **Dugel PU.** Retina Times 2008 Summer; 26(25): 20-1

**2007**

***Why You Should Own an Ambulatory Surgery Center*.** **Dugel PU**. Retina Times 2007 Spring; 25(20): 24-6

***New Paradigms for AMD Drugs: Practice Challenges and Strategies*.** **Dugel PU**. Retina Times 2007 Fall; 25(22): 34

***The Genentech Effect*.** **Dugel PU**. Retina Times 2007 Winter; 25(23): 6-8

***New Regulations for Reimbursement in Ambulatory Surgery Centers.*** **Dugel PU**, Romansky MA, Rich WL. Retina Times 2007 Winter; 25(23): 24-5

***23-Gauge Efficiency*. Dugel PU**. Retina Times 2007 Winter; 25(23): 38-40

Spirn MJ, Regillo CD. Participants: David S. Boyer, MD, Jay S Duker, MD, Pravin U. Dugel, MD, Derek Y. Kunimoto, MD JD, Adam A. Martidis, MD.

***Clinically Significant Macular Edema*.** Retina Times 2007 Winter; 25(23): 31-3

**Book Chapters**

**2004**

**Dugel PU** and Smith RE: Pars Planitis. In: Ryan, SJ, Eds. (Fourth edition), Mosby, St. Louis.

**1998**

**Dugel PU**: Ocular Neoplasm in AIDS. In: Ophthalmology, Yanoff, M, and Duker, J, ed, Mosby London.

**Dugel PU:** Ocular Manifestations of AIDS. In: Ophthalmology, Yanoff, M, and Duker, J, ed, Mosby, London.

**Dugel PU:** and Ober RR: Vitreoretinal manifestations of blunt ocular trauma. In: Retina, Ryan, S.J., Ed (third edition), Mosby, St. Louis

**Dugel PU**: and Smith RE: Pars Planitis. In: Retina, Ryan, SJ Ed., (third edition), Mosby, St. Louis

**1996**

**Dugel PU:** Ocular Syphilis. In: Ophthalmology, Yanoff, M, and Duker, J, ed, Mosby, London.

**1994**

Ryan SJ, Stout JT, **Dugel PU**: Penetrating ocular trauma. In: Retina, Ryan, S.J., ed., (second edition), Mosby, St. Louis.

Ryan SJ, Stout JT, **Dugel PU**: Subretinal neovascularization. In: Retina, Ryan, S.J., ed., (second edition), Mosby, St. Louis.

Ryan SJ, **Dugel PU**, Stout JT: Bird shot retinochoroidopathy. In: Retina, Ryan, SJ, ed., (second edition), 1994, Mosby, St. Louis.

**Dugel PU**, Ober RR. Vitreoretinal Manifestations of blunt ocular trauma. In: Retina, Retina, Ryan, SJ, ed., (second edition), Mosby, St. Louis.

**Dugel PU**, Smith RE: Pars planitis. In: Retina, Ryan, SJ, ed., (second edition), Mosby, St. Louis.

**Dugel PU,** Rao NA, Smith RE: Cataract extraction in patients with uveitis. In: Recent developments in uveitis. Desnouchamps, C., Vorougstrate, C., Caspeis, L., and Tassignon, M.J. (eds.), Kugler, Amsterdam.

**Dugel PU,** Rao NA, Smith RE: Stepwise approach to management of pars planitis . In: Recent development in uveitis. Desnouchamps, C., Vorougstrate, C., Caspeis, L., and Tassignon, M.J. (eds.), Kugler, Amsterdam.

**1993**

**Dugel PU**, and Ryan, SJ: Penetrating ocular trauma. In: Medical and Surgical Retina: Advances, Controversies, and Management, Lewis, H, and Ryan, SJ, eds., Mosby, St. Louis.

**Dugel PU,** Ober RR: Retinal manifestations of blunt trauma. In: Medical and Surgical Retina: Advances, Controversies, and management, Lewis, H., and Ryan, S.J., eds., Mosby, St. Louis.

**Book Review**

**Dugel PU**, Sadun AA: Ocular histopathology – a guide to differential diagnosis by C.E. Margo and H.E. Grossniklaus. Ocular Surgery News.

**Correspondence**

**1995**

**Dugel PU**, Smiddy WE, Frazier Byrne S, Hughes JR, Gass JDM: Ultrasound of macular holes. Ophthalmology. 102:336-337

Rutzen AR, Ortega-Larrocea G, **Dugel PU**, Chong LP, Lopez PF, Smith RE, Rao NA. Clinicopathologic study of retinal and choroidal biopsies in intraocular inflammation. Am J Ophthalmol. 119 (5): 597-611

**1992**

**Dugel PU**, Liggett PE, Lee MD, Ziogas A, Forster DJ, Smith RE, Rao NA: Repair of retinal detachment caused by cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am. J. Ophthalmol. 113(4): 468-70

**Dugel PU**, Liggett PE, Lee MD, Ziogas A, Forster DJ, Smith RE, Rao NA: Repair of retinal detachment caused by cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am. J. Ophthalmol. 113(3): 346-8

**1991**

Forster DJ, **Dugel PU**, Frangieh GT, Liggett PE, Rao NA: Rapidly progressive outer retinal necrosis in the acquired immunodeficiency syndrome. Am. J. Ophthalmol. 111:256

**Dugel PU**, Rao NA, Forster DJ, Chong LP, Frangieh GT, Sattler F, Lopresti JA: Pneumocystis carinii choroiditis after long-term aerosolized pentamidine therapy. Am. J. Ophthalmol. 111:118,

**1983 – 84**

**Dugel PU**, Heuer DR, Thach AB, Baerveldt G, Lee PP, Lloyd MA, Minckler DS, Green RL: Annular peripheral choroidal after glaucoma surgery. Ophthalmology 104

**Invited Presentations (Previous 5 years)**

**2018**

**Hawaiian Eye/Retina 2018** – January 2018

* Presenter: Diabetic Retinopathy Treatment Strategies: Efficacious vs. Sustainable
* Presenter: The Angiopoietin Pathway: The Next Great Target?
* Panelist: Diabetic Retinopathy Case Presentations
* Presenter: Symposium on DME/RVO for Allergan

**Angiogenesis -** February 2018

* Presenter: Brolucizumab Phase 3 Additional Analyses
* Presenter: Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody RG7716 in DME: Results from the Phase2 BLVD trial

**Macular Society** – February 2018

* Presenter - A Comparison of the Anatomical Efficacy of Brolucizumab and Aflibercept in Neovascular Age-Related Macular Degeneration (nAMD): An Analysis Over 16 Weeks of Matched Treatment in the HAWK and HARRIER Studies

**ARVO** - April 2018

* **4/30 POSTER PRESENTER-** Predictability of the 12-week dosing status at Week 48 for patients receiving Brolucizumab in HAWK and HARRIER, Novartis
* **4/30 Penn State PeerView CME:** Chair ARVO Symposium

**UAE for Novartis** - May 2018

* **Symposium -** CCAD Conference Presentation -Medical Retina updates, neutralizing any difference perception between anti-VEGFs
* **Abu Dhabi Retina Group** Meeting/Interesting retina cases (med/surgical)

**Orbis International** - June 2018

* Humanitarian Hospital-based program in Linyi, China (skills transfer/direct patient care)

**ASRS** - July 2018

* Instructional Course -Code Red in VR Surgery
* PRESENTER: Paper - Hawk/Harrier Brolucizumab v Aflibercept (nAMD)
* MODERATOR: Clinical Trials "unplugged"

**American Academy of Ophthalmology (AAO) –** October 2018

* Retina Subday: Brolucizumab for neovascular AMD: The 2-Year HAWK and HARRIER Results
* Academy Café: Retina
* Challenging Cases in Neovascular AMD

**2017**

**Hawaiian Eye/Retina 2017** – January 2017

* Treatment of Persistent DME/EARLY Study - speaker and presenter
* How Are We Treating Diabetic Retinopathy in 2017?

**CME Seminar - Retina 360** – January 2017

* Contemporary Concepts-scaling new Heights in Surgical Instrumentation

**Angiogenesis in Miami** – February 2017

* Anti-PDGF Therapy for Neovascular AMD - presenter

**Retina World Congress** – February 2017

* OCT Angiography Where Am I Using It? Has it Changed My Outcomes? What am I Learning from it? Panelist
* Controversies: Yes, No and When-RWC Debates - Chair Session 12
* A Novel Bispecific Anti-VEGF/Anti-Angiopoietin-2 Monoclonal Antibody for Neovascular Age-related Macular Degeneration and DME – Presenter RG7716
* First Time Presentations of Clinical Trials and Late Breakers - Chair Session 16
* Anti-PDGF in nvAMD: An Analysis of the Latest Trial Results - Presenter
* Abicipar Pegol Phase 3 AMD Studies - Presenter

**Aspen Retinal Detachment Society, Aspen** – March 2017

* **New Drugs and Targets for nAMD -** Presenter
* **Advanced Pharmacotherapy and Surgical Management for Complex Retinal Disease** - Panelist

**All Start Retinal Festival at Johns Hopkins –** May 2017

* **Treating Diabetic Retinopathy in 2017 –** Presenter

**American Academy of Ophthalmology (AAO) –** November 2017

* Advancement in Vitreoretinal Surgical Techniques: How Do I Do It? 3D Video Panel
* Patient-Reported VFQ-25 in the OASIS Study: Ocriplasmin for Symptomatic Vitreomacular Adhesion Including Macular Hole
* Academy Café: Retina
* Advances in Small-Gauge Vitrectomy
* Retina Subday: Diabetes
* Retina Subday: First Time Results of Clinical Trials

**2016**

**AZ Retina Update 2016 - Optometric Retina Society Meeting -** December 2016

* Retinal Diseases You Don’t Want to Miss – speaker
* Retina Co-management in the ICD-10 Era – speaker/panelist

**Atlantic Coast Retinal Club** -Anti-VEGF Resistance in Neovascular AMD: Role of PDGF (January) – January 9th, New York

**Angiogenesis, Exudation, and Degeneration 2016** – February 6th, Florida

* AKB-9778 in the Treatment of Diabetic Retinopathy:
* Results from the TIME-2 Study Optimizing regimen of neovascular AMD therapy via combined PDGF/VEGF antagonism

**ARVO** – Presenter, Safety of Brolucizumab vs Aflibercept (May) – May 4th, Washington

**USC Annual Symposium** – Presenter - Diabetic Retinopathy: A Paradigm Shift in Understanding and Treatment. June 17th, California

**Cole Eye Institute** – PRESENTER at Cole Eye Institute Imaging Summit-OCT Angiography...Information or Misinformation (August) – August 9th, California

**ASRS - EXPERT PANEL DISCUSSION**-presenter/abstract: A Novel Anti-VEGF/Anti-Angiopoietin2 wAMD and DME – August 10th, California

**Zeiss Symposium Faculty** – Presenter – August 11th, California – Presenter and Faculty for Zeiss Symposium

**FACULTY/Presenter AVTT Chicago** – August 26th, Illinois

* Health Care Networks: Will Your Practice Survive?
* Vitrectomy Fluidics
* Important Factors to Consider in Choosing a Practice
* Digitally Assisted Vitreoretinal Surgery

**Euretina Chair – AMD Panel for Ophthalmology Futures** – AMD is the Pipeline Dry, September 8th, Copenhagen

* Presenter - Intravitreal Therapy, TALK: Update in indications, substances and results, September 8th, Copenhagen Denmark
* Presenter - 3D Heads Up: Vitrectomy Current Evolution 2016, September 8th, Copenhagen Denmark
* Presenter - A novel anti-VEGF/Anti angiopoientin2 for wAMD and DME, September 9th, Copenhagen Denmark
* Presenter - OASIS: A 2 Year Study, September 10th, Copenhagen
* Chair/presenter – Novelties and late-breaking developments in Retina and Technology, September 10th, Copenhagen Denmark
* Chair/presenter - NOVARTIS Symposium CHAIR/SPEAKER - The Unmet Medical Need in AMD, September 10th, Copenhagen Denmark
* Presenter - The Next Frontier in Vitreoretinal Surgery: New Visualization and Surgical Techniques RETINA tech Session, September 10th, Copenhagen Denmark
* Co-Chair - Macula Society sponsored session-Most Exciting New Drugs/Devices in Pipeline, September 10th, Copenhagen Denmark
* Presenter - Macula Society sponsored session – wet AMD, September 10th, Copenhagen Denmark

**2015**

**Hawaiian Eye 2015**: Speaker: Lessons From the HARBOR Study That Should Change Your Practice; Speaker: Combination Anti-PDGF Treatment for Exudative AMD: The Anti-Fibrosis Effect; Speaker: Practical Strategies for Using Ocriplasmin in Symptomatic Vitreomacular Adhesion; Panelist: How Are We Treating Wet AMD in 2015: A Roundtable Discussion; Panelist: Multi Modal Treatment of Diabetic Retinopathy: A Roundtable Discussion; Panelist: Treatment Strategies for Retinal Venous Occlusion; Panelist: RETINAWS: A Comprehensive Course in Vitreoretinal Surgery

**Angiogenesis, Exudation, and Degeneration 2015, FL** – Speaker: Anti-PDGF Pretreatment in AMD - Results of a Pilot Study Evaluating VEGF/PDGF Crosstalk

**38th Annual Macula Society, AZ February 2015** – Presenter - The Macula Society was founded in 1977 when Dr. Lawrence J. Singerman recognized the need for a forum to present and critique the rapidly expanding new research in retinal vascular and macular disease.

**ARVO Denver 2015, CO** April 2015 – Speaker – ARVO is the largest and most respected eye and vision research organization in the world. Our members include nearly 12,000 researchers from over 75 countries.

**DOC Leipzig 2015 Germany –** June 2015 – Speaker - Beyond anti VEGF Therapy for AMD-DOC 2015 in Leipzig Germany, June 11th

**USC 40th Anniversary June 2015 California –** Symposium Speaker - Anti-VEGF resistance in neovascular AMD: Role of PDGF antagonism, June 19th

**Stealth Bio Therapeutics Ophthalmology Day** June 2015 Massachusetts – Speaker - Role of mitochondria in ophthalmology – Current treatment landscape

**MaculART Paris 2015** – June – Presenter Anti-VEGF resistance in neovascular AMD: role of PDGF antagonism

**American Academy of Ophthalmology (AAO)** – November 2015 – Retina Subspecialty Day Chairman

**2014**

**GLF Research**: Speaker: Morphologic Correlation of Visual Outcome with Anti-PDGF Combination Treatment in Exudative, AMD; Panelist: AMD and Ophthalmology Trends, 8-9 February 2014

**World Ophthalmology Conference**: Speaker: Controversies in Anti-VEGF Therapy; Understanding Differences in New Generation MIVS Machines; Dry AMD Drugs Pipeline; Recommendations of DRCR. NET in Diabetic Macular Edema; Faster and Smaller: A video presentation of new surgical techniques; Anti-VEGF Agents on Treating AMD. Presenter: Ocriplasmin: Data Driven Patient Selection Through Clinical Experience. 2-6 April 2014

**Regional Retinal Specialists Advisory Board Meeting**: Clinical expert member, 26 April 2014

**ARVO 2014**: Roundtable panelist: Advances in Small Gauge Vitrectomy; DME and Inflammation; Presenter: Allergan Advisory Board -Ozurdex Phase III Clinical Study; Clinician Experience: Why the Disease Presentation and Use of Anti VEGFs Require Individualized Treatment; Moderator: Acucela SAB; Poster Presenter (first author): Phase 1 Single Ascending Dose Study of an Intravitreal anti-C5 Monoclonal Antibody (LFG316) in Patients with Advanced AMD. 3-5 May 2014

**Rethink VMT 2014**: Speaker: Jetrea Pivotal Studies: Efficacy, Predictors of Response and Safety Profile, 17 May 2014

**Alcon Scientific Advisory Board**: Presenter: Reimbursement Issues, Obstacles, Handling Enquiries and Expectations, Logistics, Education Opportunity and Materials, 31 May 1014

**ASRS 2014**: Speaker: Ocriplasmin Clinical Update; Panelist: Nov/Dec Issue of Retinal Physician; Presenter: Management of VMA in the 21st Century: Surgical and Medical Treatment Strategies – An Expert Case Exchange; Moderator: AMD Neovascular 2 Symposium. 10-12, August 2014

**Euretina 2014: Speaker**: Forging the Future in nAMD: the Role of Anti-VEGF and Novel Therapeutic Targets; The Evolutionary Steps in Vitreoretinal Surgery; Presenter: Jetrea Symposium – Patient Experience with Ocriplasmin Including the Safety Profile, Neuroprotection of the Retina: Now and the Future; Panelist/Presenter: Jetrea Users Meeting; Moderator: Ophthalmology Futures European Forum; Alcon Symposium/Jetrea; Panelist: Therapeutic Pipeline for Preventing Visual Disability from Retinal Disease. 11-14, November 2014

**Sally Letson Symposium**: Program Chair: Global Impact of Retinal Innovations, 18-20 September 2014

**2013**

**Retina 2013**: Panel Discussion: How Are We Treating Wet Macular Degeneration in 2013? Presenter: Anti-PDGF Combination Treatment for Neovascular AMD. Presenter: What's the Best Approach for Treating Difficult Wet AMD Cases? 20-22-January-2013

**Macula Society**: Presenter: A Phase 2b Study of E10030, a Platelet Derived Growth Factor (PDGF) inhibitor in combination with a Vascular Endothelial Growth Factor (VEGF) inhibitor for Neovascular Age-Related Macular Degeneration (AMD). 27-28-February-2013

**Vit-Buckle Society (VBS)**: Presenter: Ocriplasmin: the importance of patient selection. Presenter: Anti-PDGF and Anti-VEGF Therapies for Neovascular Macular Degeneration. Presenter: Vitrectomy: Surgical Techniques and Clinical Pearls. 11-14-April-2013

**ARVO 2013**- Presenter: What's Next In The Management Of Wet AMD?. Presenter: Business of Retina: What's Important to Know in 2013. Presenter: A Phase 2 Double-masked, Placebo-controlled, Dose Ranging Study of Emixustat Hydrochloride (ACU-4429) in Subjects with GA Associated with Dry AMD. 3-8-May-2013

**Pan-American Congress of Ophthalmology with the XXXVII Brazilian Congress of Ophthalmology 2013**: Presenter: How Should We Choose an Anti-VEGF. Presenter: Combination Therapy with Anti – PDGF. Presenter: International Retina Education Conference: Atrophic Macular Degeneration. 15-18-August-2013.

**ASRS 2013**: Presenter: Tips on Macular Surgery techniques for beginners. Moderator: ASRS Research and Development Committee Symposium: Clinical Trials “Unplugged”: Real, Practical Questions and Answers. 22-28-August-2013

**Retina Society 2013**: Presenter: Safety Evaluation of Two or More Dexamethasone Intravitreal Implants for Treatment of Macular Edema Associated with RVO (The SHASTA Study). 27-September-2013

**Euretina 2013**: Presenter: Symposium- anti-VEGF therapies for patients with wet AMD-minimizing risks and maximizing outcomes. 28-September-2013

**AAO 2013**: Moderator and Presenter: Chronic Anti-VEGF Therapy: Are There Systemic Safety Concerns? Instructor: Challenging Cases in Neovascular AMD. Moderator: "Pharmacologic Treatment of Vitreomacular Traction Syndrome". Panelist: Retina, Vitreous Original Paper Session. 14-19-November-2013

**Journal Scientific Review Committee**

**1992 – Present** Retina

**1992 – Present** American Journal of Ophthalmology

**1993 – Present** Archives of Ophthalmology

**1993 – Present** Ophthalmology

**1998 – Present** Ophthalmic Surgery and Lasers

**2005 – Present** Retinal Times

**2007 – Present** Retinal Physician

**2008 – Present** Retina Today

**Scientific Advisory Board**

**2002 – Present** Alcon Surgical (RACII)

**2004 – Present**  Genentech

**2007 – Present** MacuSight

**2007 – Present** Novartis

**2007 – Present** NeoVista

**2008 – Present** ArticDX

**2009 – Present** Alcon Pharmaceutical

**2009 – Present** AMO

**2009 – Present** Novartis

**2009 – Present** Thrombogenics

**2010 – Present** Santen

**2011 – Present** Ophthotech

**2011 – Present** Lux BioScience

**2011 – Present** Digisight

**2012 – Present** Roche

**2012 – Present** Genentech

**2012 – Present** Acucela

**2013 – Present** Stealth Biotherapeutics

**2014 – Present** Lutronic

**2014 – Present** Avalanche

**2014 – Present** TrueVision

**2014 – Present** Alimera Sciences

**2014 – Present** Orbis International

**2014 – Present** Annidis

**2014 – Present** Neurotech

**2015 – Present** Aerpio

**2015 – Present** DOSE Medical

**2015 – Present** Omeros

**2015 – Present** Shire Human Genetics

**2015 – Present** Opthea

**2016 – Present** Graybug Vision

**2017 – Present** CDR-Life Inc.

**2017 – Present** Clearside Biomedical

**Consultant**

**1998 – 2000** Bausch + Lomb Surgical

**2000 – Present** Bausch + Lomb Pharma

**2006 – Present** Genentech

**2006 – Present** Alcon Surgical

**2006 – Present** Alcon Pharmaceutical

**2006 – Present** NeoVista

**2007 – Present** MacuSight

**2008 – Present** ArticAx

**2009 – Present** ORA

**2009 – Present** Novartis

**2010 – Present** Allergan

**2010 – 2011** Regeneron

**2010 – Present** Santen, Inc.

**2010 –2014** QLT, Inc.

**2010 – 2013** Abbott/AMO

**2010 – Present** Thrombogenics

**2011 – Present** Ophthotech

**2011 – Present** Lux BioScience

**2011 – Present** DigiSight

**2012 – Present** Genentech

**2012 – Present** Roche

**2012 – Present** TopCon

**2012 – Present** Acucela

**2013 – Present** Pentavision

**2013 – Present** ORA

**2013 – Present** Stealth Biotherapeutics

**2013 – Present** Annidis

**2013 – Present** Clearside Biomedical

**2014 – Present** Optovue

**2014 – Present** Pentavision

**2014 – Present** Neurotech

**2014 – Present** Lutronic

**2014 – Present** Alimera Sciences

**2015 – Present** DOSE Medical

**2015 – Present** Aerpio

**2015 – Present**  Omeros

**2015 – Present** Shire Human Genetics

**2015 – Present** Opthea

**2016 – Present** Graybug Vision

**2017 – Present** Irenix

**2017 – Present** ByeOnics

**2017 – Present** Clearside Biomedical

**2017 – Present** PanOptica

**2017 – Present** Allegro Ophthalmics LLC

**2017 – Present** Chengdu Kanghong Biotechnology

**2017 – Present** SciFluor Life Sciences

**2017 – Present** Boehringer Ingelheim

**2017 – Present** Kodiak Sciences